

## Cardiopulmonary exercise testing in neuromuscular disease: a systematic review

Gabriela Barroso de Queiroz Davoli, Bart Bartels, Ana Claudia Mattiello-Sverzut & Tim Takken

To cite this article: Gabriela Barroso de Queiroz Davoli, Bart Bartels, Ana Claudia Mattiello-Sverzut & Tim Takken (2021) Cardiopulmonary exercise testing in neuromuscular disease: a systematic review, Expert Review of Cardiovascular Therapy, 19:11, 975-991, DOI: [10.1080/14779072.2021.2009802](https://doi.org/10.1080/14779072.2021.2009802)

To link to this article: <https://doi.org/10.1080/14779072.2021.2009802>



© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



View supplementary material [↗](#)



Published online: 29 Dec 2021.



Submit your article to this journal [↗](#)



Article views: 413



View related articles [↗](#)



View Crossmark data [↗](#)

REVIEW



## Cardiopulmonary exercise testing in neuromuscular disease: a systematic review

Gabriela Barroso de Queiroz Davoli <sup>a</sup>, Bart Bartels <sup>b</sup>, Ana Claudia Mattiello-Sverzut <sup>a</sup> and Tim Takken <sup>b</sup>

<sup>a</sup>Ribeirão Preto Medical School, University of São Paulo, Brazil; <sup>b</sup>Child Development & Exercise Center, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands

### ABSTRACT

**Introduction:** Cardiopulmonary exercise testing (CPET) is increasingly used to determine aerobic fitness in health and disability conditions. Patients with neuromuscular diseases (NMDs) often present with symptoms of cardiac and/or skeletal muscle dysfunction and fatigue that might impede the ability to deliver maximal cardiopulmonary effort. Although an increasing number of studies report on NMDs' physical fitness, the applicability of CPET remains largely unknown.

**Areas covered:** This systematic review synthesized evidence about the quality and feasibility of CPET in NMDs and patient's aerobic fitness. The review followed the PRISMA guidelines (PROSPERO number CRD420211068). Between September and October 2020 one independent reviewer searched the PubMed/MEDLINE, EMBASE, SCOPUS, and Web of Science databases. Excluding reviews and protocol description articles without baseline data, all study designs using CPET to assess adult or pediatric patients with NMDs were included. The methodological quality was assessed according to the American Thoracic Society/American College of Chest Physicians (ATS/ACCP) recommendations.

**Expert opinion:** CPET is feasible for ambulatory patients with NMDs when their functional level and the exercise modality are taken into account. However, there is still a vast potential for standardizing and designing disease-specific CPET protocols for patients with NMDs. Moreover, future studies are urged to follow the ATS/ACCP recommendations.

### ARTICLE HISTORY

Received 3 September 2021  
Accepted 19 November 2021

### KEYWORDS

Exercise test; exercise modality; feasibility; muscle disease; rehabilitation; aerobic fitness

## 1. Introduction



Neuromuscular diseases (NMDs) are a heterogeneous and complex group of inherited or acquired disorders involving one or more components of the motor unit (motor neuron, peripheral nerve, neuromuscular junction, and skeletal muscle) [1,2]. Because of the disease-specific muscle weakness and fatigue, these patients exhibit limited physical activity, contributing to deconditioning and creating a 'vicious cycle' of activity discouragement and overall deconditioning [3]. In addition to that, some subtypes of NMDs, such as patients with muscular dystrophy, also suffer from cardiomyopathy and conduction disorders, which also prevent them from fully engaging in exercise [3,4].


Cardiopulmonary exercise testing (CPET) is an incremental test with gas exchange measurement and is performed up to the tolerance limit or until indications for termination [5]. It provides the investigator with information on the integrative exercise response of multiple physiological systems (cardiovascular, pulmonary, hematopoietic, neuropsychologic, and skeletal muscle) to meet the increased metabolic demand for oxygen uptake and carbon dioxide production of the active muscles during exercise [5,6]. This is possible because the pattern of oxygen uptake ( $\text{VO}_2$ ), ventilation (VE), and carbon dioxide output ( $\text{VCO}_2$ ) measured breath by breath reflects the efficiency of the heart, lungs, blood circulation blood,

pulmonary blood flow, and peripheral oxygen [5]. Therefore, the use of CPET is possible to distinguish the dominant physiological system that limits exercise performance (cardiac, pulmonary, muscle metabolism, or deconditioning), optimizing the therapeutic decision-making process [7].

The noninvasive feature of CPET and its usefulness lead to an increased interest in using it to assess exercise limiting factors and the efficacy of interventions in patients with NMDs. For example, Rapin et al. [8] were able to identify peripheral factors as the main limitation to exercise in adults with muscular dystrophies, metabolic myopathies, and hereditary peripheral neuropathies. Crescimanno et al. [9] observed a slight increase in the aerobic fitness of patients with glycogen storage disease type II in 36 months of enzyme replacement therapy, and Wiesinger et al. [10] prescribed and assessed the efficacy of a six-week aerobic training for adults with inflammatory myopathy.

Despite those informative findings using CPET in NMDs, no previous study has assessed the safety, quality, and applicability of CPET for this group. The study of such aspects is important because CPET is an intense stress test first developed to assess patients with cardiovascular and pulmonary diseases [6]. Most patients with NMDs have high levels of fatigue and present weaker muscles, more susceptible to contraction-induced muscle fiber injury, than patients with cardiac or

**CONTACT** Tim Takken  [t.takken@umcutrecht.nl](mailto:t.takken@umcutrecht.nl)  Child Development & Exercise Center, Wilhelmina Children's Hospital, University Medical Center Utrecht, Heidelberglaan 100 3584 CX, Utrecht, The Netherlands

 Supplemental data for this article can be accessed [here](#)

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.  
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

**Article highlights**

- Standardization in CPET protocols is needed because of low adherence to ATS/ACCP recommendations;
- High completion rates and few adverse events support the feasibility of CPET in pediatric and adult patients with NMD;
- Low cardiopulmonary stress (e.g. low peak heart rate), despite high metabolic demand (e.g. peak respiratory exchange ratio >1), might be a feature of NMDs, except for patients with glycogen storage disease or motor neuron disease;
- The upright cycle ergometer with ramp-wise increments is advisable to assess various ambulatory adults and some pediatric patients with NMD;
- On the treadmill, the Naughton and the Dubowy protocols are alternatives for some adults and the young patients with NMD when an upright cycle ergometer is not available.

pulmonary disease. Therefore, an intense test as the CPET could be detrimental for some NMDs.

Regarding that, this review has four aims: (1) to identify and synthesize evidence about the available CPET protocols for NMDs, (2) to evaluate the quality and feasibility of these protocols, (3) to assess the aerobic fitness of patients with NMDs and (4) to provide recommendations about the use of CPET for this group. We are investigating these properties because the technical quality and delivered effort's quality guarantee the appropriate interpretation of CPET outcomes in clinical practice and research. Moreover, information about completion rate and adverse events can address whether the CPET protocols are practical and suitable for this group or if adaptations are needed. We hypothesize that the available CPET protocols are feasible for patients with a high functional level, such as ambulatory patients, and that innovations and adaptations are needed to use this test in weaker patients.

## 2. Methods

This systematic review of the literature is reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [11], and it was registered in the International Prospective Registry of Systematic Reviews (PROSPERO) under the number CRD42020211068.

### 2.1. Data source and search strategy

Following the approach of Bramer et al. [12], we created a systematic search strategy for the databases MEDLINE using the MESH thesaurus terms for 'NMD' and 'CPET.' NMDs included muscular dystrophies, congenital myopathies, spinal muscular atrophies, amyotrophic lateral sclerosis, post-polio myelitis, polyneuropathies, Guillain-Barre syndrome and myasthenia gravis. Consecutively, this search strategy was adapted to the databases EMBASE, SCOPUS, and Web of Science. An example of this search strategy is shown in Supplementary Material A.

Between September and October 2020, one reviewer (GD) independently searched all databases and selected the relevant articles based on titles and abstracts. Subsequently, the full-text articles of selected studies were checked for compliance with the selection criteria described below. If there was

doubt, a second reviewer (TT) was consulted for the decision on the included articles. Relevant reference lists were also hand-searched to identify additional records. The selection process was supported by an online version of Endnote software (Endnote Clarivate Analytics®).

### 2.2. Selection criteria for eligible articles

#### 2.2.1. Study design and language

Cross-sectional observational studies, cohort-studies, case-reports or control studies, randomized or quasi-randomized clinical trials, and protocol descriptions of clinical trials with baseline data written in English, Portuguese, Spanish, Dutch, German, or French, were included. Narrative literature reviews, systematic reviews, protocol descriptions of clinical trials without baseline results, or studies of which the full text was not available, were excluded.

#### 2.2.2. Participants

Patients with NMD, without restriction to sex and age, were included.

Studies that evaluated patients with diabetic or compression neuropathies, chronic fatigue syndrome or fibromyalgia, radiculopathy, spinal cord injuries, complex regional pain syndrome, or additional diagnoses to the NMD reported on the study's inclusion and exclusion criteria were excluded.

#### 2.2.3. Methodology

Studies that performed a CPET on patients with NMDs to assess aerobic fitness or intervention effects on aerobic fitness (e.g. training program, diet or medication), or studies that assessed the psychometric properties of CPET in this group, were included. Studies that did not describe the exercise modality, the interval and/or workload increments, or the velocity and/or grade increments of the CPET protocol, were excluded; likewise, studies, reporting submaximal exercise tests, field tests, electronically assisted tests, or anaerobic tests, were excluded.

### 2.3. Data extraction

Using a standard form, one reviewer (GD) extracted data from the included studies about (1) characteristics of the population (Tables 1 and 2), (2) characteristics of the CPET (Tables 3 and 4), (3) the quality and feasibility of CPET (Tables 5 and 6) and (4) aerobic fitness of the patients (Tables 7 and 8). If there was doubt, a second reviewer (TT), was consulted. The percentages of the predicted peak oxygen uptake ( $VO_{2peak}$ ) and peak heart rate ( $HR_{peak}$ ) were calculated following reference values for exercise modality and age [7,13–15].

### 2.4. Methodological quality

The recommendations of the American Thoracic Society/American College of Chest Physicians (ATS/ACCP) for CPET methodology, which include standard information about equipment, modality, protocol, conduct of the test, monitoring, safety and personal issues, were used to determine the methodological quality of included studies [6].

**Table 1.** Study population characteristics – Adults.

Exercise Modality	NMD sub classification	Disease	Studies (n)	Patients (n)	Sex (M/F)	Age (Mean-SD)	Range
UPC	GSD	GSD II, V, VII	19	114	65/49	39.0 (11.4)	16–70
	MitoD	MELAS, PEO, RRFD, CPTD	29	325	139/186	38.0 (10.7)	13–96
	GSD, MitoD	—*	1	9	6/3	49.0	28–66
	IHM	MD, FSHD, LGMD, CMYo, CCD, NM, HMM Dystrophies, Myopathies	8	111	74/37	35.1 (8.6)	21–65
	IM	DM, PM	6	78	23/55	51.2 (11.6)	37–78
	MND	ALS, PPS	8	200	86/39	47.5 (7.4)	22–70
	PND	HMSN	3	27	20/7	44.0 (8.5)	20–69
	NMJD	MG	2	16	8/8	54.5 (17.2)	—
	Mix*	HMSN, Dystrophies, Myopathies	2	17	15/2	29.0 (10.4)	16–49
	MND	SMA	1	14	11/3	27.0 (16.0)	10–48
RC	IHM	LGMD, MD	1	6	4/2	34.0 (5.1)	—
SRC	PND	HMSN	1	2	0/2	44.5	—
T	GSD	GSD II, V	3	17	12/5	45.2 (15.2)	16–72
	MitoD	—*	4	70	32/38	33.2 (11.7)	13–60
	IM	DM	1	45	17/28	29.0 (12.0)	10–51
	MND	ALS, PPS	2	76	44/32	54.0 (10.5)	54–76
	PND	HMSN	1	1	1/0	51.0	—
AC	MND	PPS	2	39	8/7	34.2 (4.5)	—

Legend: UPC: upright cycle ergometer; RC: recumbent cycle ergometer; SRC: semi-recumbent cycle ergometer; T: treadmill; AC: arm-crank ergometer; GSD: glycogen storage disorders; MitoD: mitochondrial disorders; IHM: inherited myopathies; IM: inflammatory Myopathies; PND: peripheral nerve disorders; NMJD: neuromuscular junction disorders; CM: cardiomyopathy; MELAS: mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes; PEO: progressive external ophthalmoplegia; RRFD: ragged red fiber disease; CPTD: carnitine palmitoyl transferase deficiency; MD: myotonic dystrophy; FSHD: facioscapulohumeral muscular dystrophy; LGMD: limb-girdle muscular Dystrophy; CMYo: congenital myopathy; CCD: central core disease; NM: nemaline myopathy; HMM: hereditary myosin myopathy; MS: multiple sclerosis; DM: dermatomyositis; PM: polymyositis; ALS: amyotrophic lateral sclerosis; PPS: post-polio syndrome; SMA: spinal muscular atrophy; MG: myasthenia gravis; HMSN: hereditary motor and sensory neuropathy; n: number; m: male; f: female; SD: standard deviation; -: not reported; \* not specified.

**Table 2.** Study population characteristics – Pediatric.

Exercise Modality	NMD sub classification	Disease	Studies (n)	Patients (n)	Sex (M/F)	Age (Mean-SD)	Range
UPC	GSD	GSD Ia, III, VII	1	3	2/1	12.2 (1.0)	12–13
	MitoD	MCAD, SCAD, MADD	3	13	9/4	11.0 (6.0)	8–20
	IHM	DMD, BMD	3	23	23/0	9.4 (2.7)	5–20
	IM	JDM	7	114	43/55	11.0 (3.6)	6–27
SC	IM	JDM	1	4	3/1	15.7 (3.5)	—
T	GSD	GSD V	1	1	1/0	8.0	—
	IM	JDM	4	52	15/27	11.0 (2.6)	5–18

Legend: UPC: upright cycle ergometer; RC: recumbent cycle ergometer; SRC: semi-recumbent cycle ergometer; SC: supine cycle ergometer; T: treadmill; GSD: glycogen storage disorders; MitoD: mitochondrial disorders; IHM: inherited myopathies; IM: inflammatory Myopathies; MCAD: medium-Chain Acyl CoA; SCAD: short-Chain AcylCoA dehydrogenase deficiency; MADD: Multiple AcylCoA dehydrogenase deficiency; DMD: duchenne muscular dystrophy; BMD: becker muscular dystrophy; JDM: juvenil dermatomyositis; n: number; m: male; f: female; SD: standard deviation; -: not reported.

We created an adapted list (Supplementary Material B) and scored all included articles on 18 different criteria. The required information was collected and double-checked by a reviewer (GD), and for each criterion met, an article was attributed one point score. Additionally, a sum score was calculated and the studies were classified as low quality ( $\leq 7$  points), sufficient quality ( $> 7$  points), moderate quality (11 to 14 points) and high quality ( $\geq 14$  points of the maximum score of 18).

## 2.5. Analysis and data synthesis

The information on CPET protocols and outcome parameters obtained from the included studies were qualitatively summarized in overview tables and text. To facilitate the interpretation, the data were grouped based on the sub-classifications of the NMDs and the exercise modality. The NMDs were grouped as: (1) Glycogen storage disorders (GSD), (2) Mitochondrial disorders (MitoD), (3) Inherited

myopathies (IHM), (4) Inflammatory myopathies (IM), (5) Motor neuron disorders (MND), (6) Peripheral nerve disorders (PND) and (7) Neuromuscular junction disorders (NMJD) [19]. The exercise modality was classified as upright (UPC), recumbent (RC), semi-recumbent (SRC), and supine (SC) cycle ergometer, arm-crank (AC), and treadmill (T).

The quality of the CPET performance was based on the minimum test duration recommended for age range, and the number of patients that achieved the criteria of maximal effort (Tables 5 and 6). The feasibility of CPET was determined based on the percentage of patients that completed the tests and the number of adverse events reported (Tables 5 and 6), and the number of patients who achieved at least 80% of the predicted  $VO_{2peak}$  considering age and exercise modality (Tables 7 and 8). The studies with sufficient quality scores on the ATS/ACCP adapted list ( $> 7$  points), and which met the quality and feasibility criteria that supported the recommendations on how to test patients with NMDs, were included (Tables 5, 6, 9, 10).

### 3. Results

A total of 3618 articles were identified from the databases search after removing the duplicates, and another 26 articles were identified from additional sources (Figure 1). After the initial screening, 227 articles were included and assessed for eligibility. Ninety-two studies were included in the quantitative analysis, of which 74 articles assessed adults, and 18 articles assessed children and adolescents.

#### 3.1. Study design

Most studies in adults (59%,  $n = 44$ ) [8,9,20–61] and pediatric populations (61%,  $n = 11$ ) used a cross-sectional design [62–72] (Supplementary Material C). Forty-six percent of the adult studies ( $n = 34$ ) used CPET outcomes to determine the metabolic and exercise response of patients with NMDs [8,20,21,23,24,26–31,33–35,37–44,46–49,51,57,59–61,73–75], and 38% of studies ( $n = 28$ ) to prescribe exercise intensity and assess the efficacy of an intervention, medication or diet supplement [9,10,58,76–100]. In the pediatric population, most of the studies (61%,  $n = 11$ ) used CPET outcomes to understand the metabolic and exercise response [63,67–72,101–104], and only 17% of the studies ( $n = 3$ ) aimed to prescribe exercise intensity and assess the efficacy of an intervention or another therapy [105–107].

#### 3.2. Characteristics of the population

A total of 1237 adults (m, 625; f, 513) and 210 children and adolescents (m, 96; f, 88) with NMD were assessed in the included studies ( $n = 92$ ) (Tables 1 and 2). Three articles did not report the gender of patients [64,65,76]. An overview of the included studies is shown in the Supplementary Material C. In general, the adult patients were ambulatory (with or without assistive devices) or able to cycle [8,9,20–26,73,76–84,108]. They were inactive, with moderate exercise intolerance [9,25,27–31,74–88], and did not have symptomatic cardiac or pulmonary disease [23,26,31–36,73,75,77,89–92]. The pediatric patients were also ambulatory with or without using assistive devices [63,66,101] and sedentary [105,106]. Specifically, for patients with inflammatory myopathy, three studies assessed patients with active and inactive myositis [67,68,102], and two other studies only assessed patients with active [69] and inactive myositis [70].

#### 3.3. Characteristics of the CPET

Information about the CPET protocol is presented in Tables 3 and 4. The upright cycle ergometer exercise modality for CPET was used in 84% ( $n = 62$ ) of the adult studies [8,10,20–31,34,36,38–44,46–56,59,61,66,73–80,83,85–88,90–92,94–100,108], evaluating most adult patients with mitochondrial disease ( $n = 325$ ) and 67% ( $n = 12$ ) of pediatric studies [63,65–




Figure 1. Flowchart of search and selection process.



69,72,101–103,106] and young patients with inflammatory myopathy (n = 114). Most upright cycle ergometers were electromagnetically braked (48%, n = 30/62 and 83%, n = 10/12, adults and children, respectively) [22,23,25–29,31,34,35,38,39,41,44,52–54,58,59,63,65–69,79,83,85,88,90,95–98,102,103,106,108]. The treadmill was only used in 13% (n = 10/74) of the adult [9,33,37,42,45,57,60,82,89,93] and 28% (n = 5/18) of pediatric studies [62,64,104,105,107], and most studies assessed adult patients with motor neuron disease (n = 76) and young patients with inflammatory myopathy (n = 52). In both adult and pediatric populations, few studies adopted other exercise modalities. The recumbent cycle ergometer (n = 1) [81], semi-recumbent cycle ergometer (n = 1) [46], and arm-crank ergometer (n = 2) were only reported in adults [32,74], and one study assessing children/adolescents used a supine recumbent cycle ergometer [70]. Moreover, two studies used more than one device: the upright cycle ergometer and treadmill, and the upright cycle ergometer and arm-crank [42,74].

In the adult population, 42% of studies with the upright cycle ergometer (n = 26) [8,22,23,28,34–36,40,43,44,56,68,73,75,76,79,80,86,90,91,94–97,99,100], three studies with the treadmill [37,89,93] and one with the recumbent cycle ergometer [81] and arm-crank [32] reported the warm-up as part of the CPET protocol. For the pediatric population, more than half of the studies using the upright cycle ergometer (67%, n = 8/12) [63,66,67,69,72,102,103,106], and one study using the treadmill [104] and supine cycle ergometer [70] reported the warm-up period (Tables 3 and 4). This initial

phase of the protocol was most often performed by adults with motor neuron disease (n = 172) and by children with inflammatory myopathies (n = 76).

Concerning the exercise protocol and work increment for cycle ergometers, most studies in the adult population used step protocols (73%, n = 48/66) [10,20,22,24–26,29–31,34,38,39,41–44,46–53,55–59,61,74,75,77,78,80,83,84,86–88,90–92,94–96,98,99,108] and individualized workload increments (62%, n = 41/66) [8,19,22–25,27,28,30–32,36,40,42,44,46,47,49–52,54–56,58,59,61,74,76,80,81,84,85,88,92,96–98,100]. Some exceptions were the studies with inflammatory myopathies at the upright cycle ergometer that used set workload increments (83%, n = 5) (Table 3) [10,21,43,48,87]. This protocol selection for the upright cycle ergometer differs from the one observed in the studies that assessed children and adolescents, where most upright cycle ergometer studies use a ramp protocol, which is characterized by the continuous increase of work rate, and individualized increments of workload (75%, n = 9/12) [66,67,69,71,72,101–103,106]. Only for the supine cycle ergometer was a step protocol used (Table 4) [67]. For treadmills, the protocol that was used varied between the studies. The Naughton (speed increment: 0.8 km/hr and grade: 3.5% each 3 minutes) and the Bruce protocols (speed increment: 1.3–1.5 km/hr and grade: 2% each 3 minutes) were selected for the adult population with glycogen storage disorders (n = 2) [9,42,57], and a protocol developed by Ortega [109] (constant self-selected speed and grade increment in 5% each 3 minutes) was selected for patients with mitochondrial disorders (n = 2) [33,41]. In

Table 3. Characteristics of CPET – Adults.

Exercise Modality	NMD sub classification	Disease	Studies (n)	Warm-up (n)	Ergometer (n)		Exercise protocol (n)		Work increment (n)	
					M	E	R	S	Set	Ind.
UPC	GSD	GSD II, V, VII	19	5	1	9	2	17	5	14
	MitoD	MELAS, PEO, RRF, CPTD	29	8	2	21	7	22	9	20
	GSD, MitoD	*	1	1	–	–	1	1	–	1
	IHM	MD, FSHD, LGMD, CMYo, CCD, NM, HMM Dystrophies, Myopathies	8	4	1	2	2	7	1	7
	IM	DM, PM	6	1	–	2	1	5	5	1
	MND	ALS, PPS	8	5	1	2	3	5	3	5
	PND	HMSN	3	3	1	2	2	2	1	2
	NMJD	MG	2	2	1	1	–	2	–	2
	Mix*	HMSN, Dystrophies, Myopathies	2	1	2	1	–	2	1	1
	MND	SMA	1	1	–	1	1	–	–	1
RC	IHM	LGMD, MD	1	–	–	–	–	1	–	1
SRC	PND	HMSN	1	–	–	–	–	1	–	1
AC	MND	PPS	2	1	–	–	1	–	1	1
Exercise Modality	NMD sub classification	Disease	Studies (n)	Warm-up (n)	Exercise protocol					
					Naughton [16]	Bruce [17]	Balke [18]	Ortega [109]	Other [89]	
T	GSD	GSD II, VPompe, McArdle	3	–	2 <sup>&amp;</sup>	2	–	–	–	
	MitoD	*	4	–	1	1	–	2	–	
	IM	DM	1	1	–	–	1	–	–	
	MND	ALS, PPS	2	1	1	–	–	–	1	
	PND	HMSN	1	1	–	–	1	–	–	

Legend: UPC: upright cycle ergometer; RC: recumbent cycle ergometer; SRC: semi-recumbent cycle ergometer; T: treadmill; AC: arm-crank ergometer; GSD: glycogen storage disorders; MitoD: mitochondrial disorders; IHM: inherited myopathies; DAMC: disorders of activation of muscle contraction; IM: inflammatory Myopathies; PND: peripheral nerve disorders; NMJD: neuromuscular junction disorders; CM: cardiomyopathy; MELAS: mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes; PEO: progressive external ophthalmoplegia; RRF: ragged red fiber disease; CPTD: carnitine palmitoyl transferase deficiency; MD: myotonic dystrophy; FSHD: facioscapulohumeral muscular dystrophy; LGMD: limb-girdle muscular Dystrophy; CMYo: congenital myopathy; CCD: central core disease; NM: nemaline myopathy; HMM: hereditary myosin myopathy; DM: dermatomyositis; PM: polymyositis; ALS: amyotrophic lateral sclerosis; PPS: post-polio syndrome; SMA: spinal muscular atrophy; MG: myasthenia gravis; CM: cardiomyopathy; FA: friedreich's ataxia; BTHS: barth syndrome; HMSN: hereditary motor and sensory neuropathy; n: number of studies; m: mechanically; E: electrically; R: ramp; S: step; Ind.: individualized; min: minute. SD: standard deviation; –: not reported; \* not specified; <sup>&</sup> One study used two different protocols.

**Table 4.** Characteristics of CPET – Pediatric.

Exercise Modality	NMD sub classification	Disease	Studies (n)	Warm-up (n)	Ergometer (n)		Exercise protocol (n)		Work increment (n)	
					M	E	R	S	Set	Ind.
UPC	GSD	GSDIa, III, VII	1	–	–	–	1	–	–	1
	MitoD	MCAD, SCAD, MADD	3	1	–	1	3	–	1	2
	IHM	DMD, BMD	3	1	–	2	2	1	1	2
	IM	JDM	7	5	–	7	5	2	1	6
SC	IM	JDM	1	1	1	–	–	1	–	1
Exercise Modality	NMD sub classification	Disease	Studies (n)	Warm-up (n)	Exercise protocol					
					Dubowy [15]	Bruce [17]	Balke [18]	Pérez [104]		
T	GSD	GDS V	1	1	–	–	–	–	1	–
	IM	JDM	4	–	1	–	–	–	–	–

Legend: UPC: upright cycle ergometer; RC: recumbent cycle ergometer; SRC: semi-recumbent cycle ergometer; SC: supine cycle ergometer; T: treadmill; GSD: glycogen storage disorders; MitoD: mitochondrial disorders; IHM: inherited myopathies; IM: inflammatory Myopathies; CM: cardiomyopathy; MCAD: medium-Chain Acyl CoA; SCAD: short-Chain AcylCoA dehydrogenase deficiency; MADD: Multiple AcylCoA dehydrogenase deficiency; DMD: duchenne muscular dystrophy; BMD: becker muscular dystrophy; JDM: juvenil dermatomyositis; BTHS: barth syndrome; FA: friedreich's ataxia; n: number of studies; m: mechanically; E: electrically; R: ramp; S: step; Ind.: individualized; min: minute; -: not reported; \* not specified .

children and adolescents, the Bruce protocol was used to assess patients with inflammatory myopathy in 75% (n = 3) of articles [62,64,107] (Table 4).

### 3.4. Quality of test performance

#### 3.4.1. Test duration

Seventeen studies (23%) in adults and eight (44%) studies in children reported the duration of the CPET. From those, four studies assessing adult patients with inflammatory myopathies (n = 1 study, 11 patients), mitochondrial disorders (n = 2 studies, 16 patients) and glycogen storage disorders (n = 1 study, 1 patient) in the upright cycle ergometer presented a mean duration below eight minutes [20,21,86,108] (Table 5). All pediatric studies reported a mean duration of the CPET above eight minutes [62–64,66,68,70,105,107].

#### 3.4.2. Criteria of maximal effort

Concerning maximal effort during the CPET, 22 studies with adult NMDs [8,9,25,29,31,32,37,43,44,47,58,59,61,76,81,88,89,92,94,98,100,108] and seven studies with pediatric NMDs presented criteria for maximal effort [37,62,64,66,68,101,103] (Table 3a and b). From these studies, adult patients with glycogen storage disorders and motor neuron disease most often performed a maximal CPET in the upright cycle ergometer (98%, n = 42, and n = 94 patients) [23,24,36,41,76,96,100]. More than 60% of the adults with mitochondrial disorders (n = 24), inherited myopathies (n = 11), inflammatory myopathies (n = 13), and peripheral nerve disorders (n = 12) met the criteria of maximal CPET in the upright cycle ergometer [8,23,28,41,43,44,48], and 64% of patients with motor neuron disease (n = 9) and 75% of patients with inflammatory myopathies (n = 6) achieved the criteria in the recumbent cycle ergometer and treadmill [9,81].

In the pediatric studies, more than 90% of patients with mitochondrial myopathy (n = 2) and inflammatory myopathy

(n = 10 and n = 4) met the maximal criteria in the upright cycle ergometer and supine cycle ergometer [67,70,101] (Table 6). This percentage was lower in inflammatory myopathies (67%, n = 10) on the treadmill [62] and in inherited myopathies (11%, n = 1) on the upright cycle ergometer [66] (Table 6).

### 3.5. Feasibility of CPET

#### 3.5.1. Measurement completion

From most of the included studies, it was possible to extract the number of patients who completed the CPET (Tables 5 and 6). In a few articles that used the upright cycle ergometer to assess adult patients with glycogen storage disorders (26%, n = 5) [22,30,35,42,53], mitochondrial disorders (27%, n = 8) [22,23,42,50,51,85,90,95], inherited myopathies (37%, n = 3) [22,50,99], motor neuron disease (75%, n = 6) [23,24,26,73–75], peripheral nerve disorders (67%, n = 2) [20,77], myasthenia gravis (n = 2) [22,79] and a mix of diseases (n = 2) [22,91], the information on feasibility was missing (Table 5). In contrast, studies assessing children/adolescents clearly present this information (Table 6).

Considering only the studies that reported the completion rate, three adults with mitochondrial disorders were unable to finish the CPET in the upright cycle ergometer, one due to syncope [20,34] and the other two because of an inability to cycle. Difficulties in cycling were also reported in another six patients with motor neuron disease [48]. In treadmill tests, only one adult with glycogen storage disorders discontinued the CPET, because of dizziness [57] (Table 5). Moreover, in the test performed at the upright cycle ergometer, three pediatric patients (with glycogen storage disorder, mitochondrial disorder, and inherited myopathy) did not complete the CPET. For the patient with glycogen storage disorder, the reason was an intense myalgia episode; for the other two patients, no explanation was given [72] (Table 6).

Table 5. Quality and feasibility of CPET – Adults.

Exercise Modality	NMD sub classification	Disease	Studies (n)	Quality of test performance			Feasibility					Safety				
				Duration		Criteria of maximal effort	Completion rate			Adverse events						
				Studies (n)	Time		Studies (n)	Patients (%)	Studies (n)	Event (n)	Studies (n)		Scale/grade			
UPC	GSD	GSD II, V, VII	19	4	11.0	4	HR <sub>peak</sub> ≥85% of predicted* RER <sub>peak</sub> >1.1 Borg <sub>peak</sub> ≥7	98	14	100	4	0	3	Borg 0–20/ 19.0	–	–
Mitochondrial	Mitochondrial	MELAS, PEO, RRF, CPTD	29	4	9.4 (2.7)	6	HR <sub>peak</sub> = & or >80% of predicted& RER <sub>peak</sub> ≥1.1–1.2 Borg <sub>peak</sub> ≥7	63	21	99	2	0/1 (Syncope)	5	Borg 0–10/ 8.0 (1.3)	–	–
	GSD, Mitochondrial	–	1	1	10.8	1	HR <sub>peak</sub> >85% of predicted#, RER <sub>peak</sub> >1.1, Borg <sub>peak</sub> ≥7	44	1	100	–	–	–	–	–	–
IHM	IHM	MD, FSHD, LGMD, CMyo, CCD, NM, HMM Dystrophies, Myopathies	8	3	13.0	3	HR <sub>peak</sub> >85% of predicted& or #, RER <sub>peak</sub> >1.0–1.1, Borg <sub>peak</sub> ≥7 or 17–19.	65	5	100	1	1 (CPK>1000) [FSHD]	2	Borg 0–20/ 19.0 (1.0)	1	CPK
IM	IM	DM, PM	6	1	5.8 (2.4)	2	HR <sub>peak</sub> >90% of predicted&, RER <sub>peak</sub> ≥1.2; BL>6.0 mmol; ΔpH>0.04; VR<20%; EqO2 > 40	62	6	100	3	0	2	Borg 0–20/ 19.0 (0.4)	–	–
MND	MND	ALS, PPS	8	2	15.3 (–)	1	RER <sub>peak</sub> >1.1	98	2	100	2	0	2	Borg 0–20/ 18.0	–	–
PND	PND	HMSN	3	1	10.8	1	HR <sub>peak</sub> >85% of predicted#, RER <sub>peak</sub> >1.1, Borg <sub>peak</sub> ≥7	67	1	100	–	–	1	Borg 0–10/ 10.0	1	CPK<170 IU/L
	NMJD	MG	2	–	–	1	HR <sub>peak</sub> ≥ predicted**, RER <sub>peak</sub> ≥1.2, BL>8.0 mmol/L, Borg <sub>peak</sub> ≥17	–	–	–	–	–	–	–	–	–
Mix*	Mix*	HMSN, Dystrophies, Myopathies	2	–	–	–	–	–	–	–	–	–	–	–	–	–
RC	MND	SMA	1	–	–	1	OMNI Scale≥8 RER <sub>peak</sub> >1.0	64	1	100	1	0	–	–	–	–
SRC	IHM	LGMD, MD	1	–	–	–	–	–	1	100	–	–	1	Borg0–20/ 16.0 (1.0)	–	–
PND	PND	HMSN	1	–	–	–	–	–	1	100	–	–	1	Borg0–20/ 16.0 (1.0)	–	–
T	GSD	GSD II, V	3	3	9.4 (5.5)	1	HR <sub>peak</sub> ≥85% of predicted& RER <sub>peak</sub> ≥1.1	–	3	94	1	1 (Dizziness)	2	Borg 0–10/ 8.5 (1.1)	–	–
Mitochondrial	Mitochondrial	–	4	3	12.1 (3.4)	1	–	–	4	100	–	–	2	Borg 0–10/ 8.4 (2.1)	–	–
IM	IM	DM	1	–	–	1	HR <sub>peak</sub> >80% of predicted&	75	1	100	–	–	1	Borg 0–20/ 18.0	–	–
MND	MND	ALS, PPS	2	–	–	1	HR <sub>peak</sub> >75% of predicted&, 55–65% of predicted VO <sub>2</sub>	–	2	100	–	–	–	–	–	–
PND	PND	HMSN	1	1	25.0	1	–	–	1	100	–	–	–	–	–	(Continued)

(Continued)



Table 5. (Continued).

Exercise Modality	NMD sub classification	Disease	Studies (n)	Quality of test performance			Feasibility				Safety		
				Duration	Studies (n)	Criteria	Patients (%)	Completion rate	Adverse events	Perception exertion	Studies (n)	Scale/grade	Studies (n)
AC	MND	PPS	2	1	9.6 (1.9)	1	BL>8.0 mmol	–	2	100	–	Borg 0–20/18.2 (0.21)	–

Legend: UPC: upright cycle ergometer; RC: recumbent cycle ergometer; SRC: semi-recumbent cycle ergometer; T: treadmill; AC: arm-crank ergometer; GSD: glycogen storage disorders; MitoD: mitochondrial disorders; IHM: inherited myopathies; DAMC: disorders of activation of muscle contraction; IM: inflammatory myopathies; PND: peripheral nerve disorders; NMJD: neuromuscular junction disorders; MELAS: mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes; PEO: progressive external ophthalmoplegia; RRED: ragged red fiber disease; CPTD: carnitine palmitoyl transferase deficiency; MD: myotonic dystrophy; FSHD: facioscapulohumeral muscular dystrophy; LGMD: limb-girdle muscular dystrophy; CMYo: congenital myopathy; CCD: central core disease; NM: nemaline myopathy; HMM: hereditary myosin myopathy; MS: multiple sclerosis; DMI: dermatomyositis; PM: polymyositis; ALS: amyotrophic lateral sclerosis; PPS: post-polio syndrome; SMA: spinal muscular atrophy; MG: myasthenia gravis; HMSN: hereditary motor and sensory neuropathy; n: number of studies; %: percentage of patients; HR<sub>peak</sub>: heart rate peak; RER<sub>peak</sub>: respiratory exchange ratio; OMNI/Borg: scale of perception exertion; PE: perception exertion BL: blood lactate level; Δph: delta of blood ph; VR: ventilatory reserve; EqO<sub>2</sub>: ventilatory equivalent for oxygen; SD: standard deviation; CPK: creatine phosphokinase; mmol: millimol; U.L: units per liter -: not reported; \* not specified; #210–0.65 x age; #220-age; # (210–0.65 x age); \*\* (208–0.7 x age)–10.

Table 6. Quality and feasibility of CPET – Pediatric.

Exercise Modality	NMD sub classification	Disease	Studies (n)	Quality of test performance			Feasibility				Safety		
				Duration	Studies (n)	Criteria	Patients (%)	Completion rate	Adverse events	Perception exertion	Studies (n)	Scale/grade	Studies (n)
UPC	GSD	GSD Ia, III, VII	1	–	–	–	–	1	67	1	1	Myalgia	–
	MitoD	MCAD, SCAD, MADD	3	–	1	HR <sub>peak</sub> >180 bpm; RER <sub>peak</sub> ≥1.0	100	3	92	–	–	–	–
	IHM	DMD, BMD	3	2	8.1 (1.4)	1	HR <sub>peak</sub> >180 bpm; RER <sub>peak</sub> ≥1.0	3	96	2	1	Elevated CPK [BMD]	2
SC	IM	JDM	7	1	8.1	2	HR <sub>peak</sub> >95% of predicted; RER <sub>peak</sub> >1.0–1.1	7	100	4	0	–	1
	IM	JDM	1	1	10.0 (2.0)	1	HR <sub>peak</sub> >180 bpm; RER <sub>peak</sub> ≥1.0	1	100	–	–	–	–
T	GSD	GSD V	1	–	–	–	–	1	100	–	–	–	–
	IM	JDM	4	4	9.0 (2.1)	2	HR <sub>peak</sub> >180bpm; RER <sub>peak</sub> ≥1.0	4	100	3	0	–	–

Legend: UPC: upright cycle ergometer; RC: recumbent cycle ergometer; SRC: semi-recumbent cycle ergometer; T: treadmill; GSD: glycogen storage disorders; MitoD: mitochondrial disorders; IHM: inherited myopathies; IM: inflammatory myopathies; MCAD: medium-chain Acyl CoA: SCAD: short-chain AcylCoA dehydrogenase deficiency; MADD: Multiple AcylCoA dehydrogenase deficiency; DMD: Duchenne Muscular Dystrophy; BMD: Becker Muscular Dystrophy; JDM: juvenile dermatomyositis; n: numbers of studies; %: percentage of patients; HR<sub>peak</sub>: heart rate peak; bpm: beats per minute; RER<sub>peak</sub>: respiratory exchange ratio; Borg: rating of perceived exertion; PE: perception exertion; SD: standard deviation; CPK: creatine phosphokinase; mmol: millimol; U.L: units per liter -: not reported; \* not specified; #220-age.

### 3.5.2. Adverse events

In general, few studies reported on the occurrence of complications or adverse events during the CPET in the adult group (upright cycle ergometer = 13, recumbent cycle ergometer = 1, treadmill = 1) [10,23,25,30,34,54,57,76,77,81,87,96,100] and in the pediatric group (upright cycle ergometer = 6, treadmill = 3) [62,64,66,67,69,72,102,103,107]. Adverse events occurred in three of the adult studies (upright cycle ergometer = 2, treadmill = 1) [34,57,77]. Each was an isolated event (one patient in each study), and most of the time connected to an interruption of the test (Table 5). One pediatric study reported an isolated adverse event with a patient with glycogen storage disorder, and one complication with a patient with an inherited myopathy (Table 6) [72].

Specific parameters for measuring the safety of CPET were only reported by two studies assessing adult patients [77,79], and by another two comprised of pediatric patients [66,72].

Most of the studies used the comparison of creatine phosphokinase (CPK) levels before and after the test, and values >150 U/L were considered elevated [79]. One study also used the rating of muscle hurt (RMH), where a score >6 indicates severe muscle pain [66].

### 3.6. Aerobic fitness of NMD patients

All NMD subgroups presented a reduced aerobic fitness (<80% of the predicted  $VO_{2peak}$ ), except adults with inflammatory myopathies using the treadmill, and pediatric patients with glycogen storage disorders using the upright cycle ergometer (81% and 82% of the predicted  $VO_{2peak}$ , respectively). The lowest aerobic fitness levels were observed in adult patients with motor neuron disease (32% of the predicted  $VO_{2peak}$ ) on the recumbent cycle ergometer (Table 7), and in pediatric patients with glycogen storage disorders (38% of the pre-

Table 7. Aerobic fitness of patients – Adults.

Exercise Modality	NMD sub classification	Disease	Studies (n)	$VO_{2peak}$ (ml/kg/min)	$VO_{2peak}$ (% of predicted)	Studies (n)	$HR_{peak}$ (bpm)	$HR_{peak}$ (%)	Studies (n)	$RER_{peak}$	Studies (n)	$W_{peak}$ (watts)
UPC	GSD	GSD II, V, VII	18	20.1	44	16	165	88	11	1.0	11	79.4
	MitoD	MELAS, PEO, RRF, CPTD	26	20.8	47	20	146	80	15	1.2	22	86.0
	GSD, MitoD	*	—	—	—	1	134	—	—	—	1	67.0
	IHM	MD, FSHD, LGMD, CMyo, CCD, NM, HMM Dystrophies, Myopathies	6	26.0	58	6	161	88	3	1.2	8	122.2
	IM	DM, PM	5	19.0	40	3	146	85	2	1.1	2	107.6
	MND	ALS, PPS	6	21.2	54	5	156	89	4	1.1	7	75.2
	PND	HMSN	2	34.0	74	1	149	84	—	—	2	128.2
	NMJD	MG	2	25.0	64	—	—	—	—	—	1	163.6
	Mix*	HMSN, Dystrophies, Myopathies	2	24.0	50	1	174	93	—	—	1	88.0
RC	MND	SMA	1	15.2	32	—	—	—	1	1.0	—	—
SRC	IHM	LGMD, MD	1	18.2	43	1	164	93	—	—	1	94.0
	PND	HMSN	1	17.1	50	1	152	82	—	—	1	102.0
T	GSD	GSD II, V	3	20.2	48	3	158	90	3	0.9	—	—
	MitoD	*	4	24.0	52	2	170	91	2	1.2	2	143.0
	IM	DM	1	40.4	81	1	190	101	1	1.1	—	—
	MND	ALS, PPS	1	28.0	61	1	92	56	—	—	—	—
AC	PND	CMT	1	30.0	71	—	—	—	—	—	—	—
	MND	PPS	1	21.5	47	1	160	87	1	1.0	1	74.5

Legend: UPC: upright cycle ergometer; RC: recumbent cycle ergometer; SRC: semi-recumbent cycle ergometer; T: treadmill; AC: arm-crank ergometer; GSD: glycogen storage disorders; MitoD: mitochondrial disorders; IHM: inherited myopathies; DAMC: disorders of activation of muscle contraction; IM: inflammatory Myopathies; PND: peripheral nerve disorders; NMJD: neuromuscular junction disorders; MELAS: mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes; PEO: progressive external ophthalmoplegia; RRF: ragged red fiber disease; CPTD: carnitine palmityl transferase deficiency; MD: myotonic dystrophy; FSHD: facioscapulohumeral muscular dystrophy; LGMD: limb-girdle muscular Dystrophy; CMyo: congenital myopathy; CCD: central core disease; NM: nemaline myopathy; HMM: hereditary myosin myopathy; MS: multiple sclerosis; DM: dermatomyositis; PM: polymyositis; ALS: amyotrophic lateral sclerosis; PPS: post-polio syndrome; SMA: spinal muscular atrophy; MG: myasthenia gravis; HMSN: hereditary motor and sensory neuropathy; n: number; m: male; f: female; SD: standard deviation;  $VO_{2peak}$ : oxygen uptake at peak of CPET; ml: milliliter; Kg: kilogram; min: minute; %: percentage;  $HR_{peak}$ : peak heart rate during CPET; bpm: beats per minute;  $W_{peak}$ : peak workload during CPET;  $RER_{peak}$ : peak respiratory exchange ratio; -: not reported; \* not specified.

Table 8. Aerobic fitness of patients – Pediatric.

Exercise Modality	NMD sub classification	Disease	Studies (n)	$VO_{2peak}$ (ml/kg/min)	$VO_{2peak}$ (% of predicted)	Studies (n)	$HR_{peak}$ (bpm)	$HR_{peak}$ (%)	Studies (n)	$RER_{peak}$	Studies (n)	$W_{peak}$ (watts)
UPC	GSD	GSD Ia, III, VII	1	40.5	82	1	190	97	1	1.0	—	—
	MitoD	MCAD, SCAD, MADD	2	36.2	79	3	182	93	3	1.2	2	134.1
	IHM	DMD, BMD	3	21.0	44	3	147	75	2	1.1	1	55.6
	IM	JDM	4	24.0	48	6	175	89	5	1.2	4	81.0
SC	IM	JDM	1	36.0	71	1	182	93	1	1.1	1	30.0
T	GSD	GSD V	1	19.0	38	1	166	83	1	0.8	—	—
	IM	JDM	4	34.0	67	2	174	87	2	1.0	—	—

Legend: UPC: upright cycle ergometer; RC: recumbent cycle ergometer; SRC: semi-recumbent cycle ergometer; SC: supine cycle ergometer; T: treadmill; GSD: glycogen storage disorders; MitoD: mitochondrial disorders; IHM: inherited myopathies; IM: inflammatory Myopathies; MCAD: medium-Chain Acyl CoA; SCAD: short-Chain AcylCoA dehydrogenase deficiency; MADD: Multiple AcylCoA dehydrogenase deficiency; DMD: Duchenne Muscular Dystrophy; BMD: Becker Muscular Dystrophy; JDM: juvenile dermatomyositis; n: number; m: male; f: female; SD: standard deviation;  $VO_{2peak}$ : oxygen uptake at peak of CPET; ml: milliliter; Kg: kilogram; min: minute; %: percentage;  $HR_{peak}$ : heart rate at peak of CPET; bpm: beats per minute;  $W_{peak}$ : peak workload during CPET;  $RER_{peak}$ : peak respiratory exchange ratio; -: not reported.

Table 9. Characteristic of the studies with sufficient score in the ATS/ACCP adapted quality list – Adults.

Exercise Modality	NMD sub classification	Disease	Studies (n)	Patients (n) [M/F]	Age (Mean-SD)	Protocol	Quality of test			Feasibility of test			Aerobic fitness				
							Studies (n)	Duration (min)	Criteria of maximal effort	Completion rate Patients (%)	Adverse events (n)	Studies (n)	VO <sub>2peak</sub> (%pred)	HR <sub>peak</sub> (%) pred	RER <sub>peak</sub>		
UPC	GSD	GSD V, VII	5	18 [10/8]	35.7 (4.8)	Start: 10–40 W Effort: 5–10 W/min (Step) or 20–30 W/2 min or 40 W/3 min Start: 20–50 W (6 min) Effort: 10–25 W/min (Ramp) Cadence: 60–80 rpm Warm-up: submaximal W/3–4 min or 20 W/1 min Effort: 5–20 W/min or 20–30 W/2 min (Step) Cadence: 50 rpm Warm-up: 0 W/4 min Effort: 5–25 W/min (Ramp) Cadence: 60–80 rpm Warm-up: 0 W/1–3 min Effort: 5–10 W/min (Ramp) Cadence: >50 rpm Start: 20–50 W/6 min Effort: 5–25 W/min (Ramp) Cadence: 60–80 rpm Warm-up: 5–15 W/min (Step) Cadence: 60 rpm Effort: 5–15 W/min (Step) Cadence: 60 rpm Warm-up: 0 W/2 min Effort: 3–20 W/min (Step) Cadence: 50–80 rpm Warm-up: 0 W/2 min Effort: 3–20 W/min (Ramp) Cadence: 60 rpm Warm-up: 0 W/1–3 min Effort: 5–10 W/min (Ramp) Cadence: >50 rpm Start: 25 W/2 min Effort: 12.5–25 W/2 min (Step) Cadence: 50–60 rpm Start: 25 W/2 min Effort: 12.5–25 W/2 min (step) Cadence: 50–60 rpm Naughton protocol (speed increment: 0.8 Km/h/3 min grade increment: 3.5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Ortega protocol (constant self selected speed, grade increment: 0–5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Modified Balke protocol (constant speed: 4.8 Km/h, grade increase: 1%/min)	2	11.5	1	HR <sub>peak</sub> ≥85% of predicted	3	100%	–	5	19.0 (42%)	172 (94%)	0.87
	MitoD	MitoD, RRFD	9	86 [24/34]	35.5 (9.0)	Warm-up: submaximal W/3–4 min or 20 W/1 min Effort: 5–20 W/min or 20–30 W/2 min (Step) Cadence: 50 rpm Warm-up: 0 W/4 min Effort: 5–25 W/min (Ramp) Cadence: 60–80 rpm Warm-up: 0 W/1–3 min Effort: 5–10 W/min (Ramp) Cadence: >50 rpm Start: 20–50 W/6 min Effort: 5–25 W/min (Ramp) Cadence: 60–80 rpm Warm-up: 5–15 W/min (Step) Cadence: 60 rpm Effort: 5–15 W/min (Step) Cadence: 60 rpm Warm-up: 0 W/2 min Effort: 3–20 W/min (Step) Cadence: 50–80 rpm Warm-up: 0 W/2 min Effort: 3–20 W/min (Ramp) Cadence: 60 rpm Warm-up: 0 W/1–3 min Effort: 5–10 W/min (Ramp) Cadence: >50 rpm Start: 25 W/2 min Effort: 12.5–25 W/2 min (Step) Cadence: 50–60 rpm Start: 25 W/2 min Effort: 12.5–25 W/2 min (step) Cadence: 50–60 rpm Naughton protocol (speed increment: 0.8 Km/h/3 min grade increment: 3.5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Ortega protocol (constant self selected speed, grade increment: 0–5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Modified Balke protocol (constant speed: 4.8 Km/h, grade increase: 1%/min)	2	10.7	1	HR <sub>peak</sub> >180 bpm or 85% of predicted; RER <sub>peak</sub> >1.00	8	86%	(n = 1) Syncope	9	23.0 (51%)	140.0 (77%)	1.30
	GSD, MitoD	*	1	9 [6/3]	49.0	Warm-up: 5–10 W/min (Step) or 20–30 W/2 min or 40 W/3 min Start: 20–50 W (6 min) Effort: 10–25 W/min (Ramp) Cadence: 60–80 rpm Warm-up: submaximal W/3–4 min or 20 W/1 min Effort: 5–20 W/min or 20–30 W/2 min (Step) Cadence: 50 rpm Warm-up: 0 W/4 min Effort: 5–25 W/min (Ramp) Cadence: 60–80 rpm Warm-up: 0 W/1–3 min Effort: 5–10 W/min (Ramp) Cadence: >50 rpm Start: 20–50 W/6 min Effort: 5–25 W/min (Ramp) Cadence: 60–80 rpm Warm-up: 5–15 W/min (Step) Cadence: 60 rpm Effort: 5–15 W/min (Step) Cadence: 60 rpm Warm-up: 0 W/2 min Effort: 3–20 W/min (Step) Cadence: 50–80 rpm Warm-up: 0 W/2 min Effort: 3–20 W/min (Ramp) Cadence: 60 rpm Warm-up: 0 W/1–3 min Effort: 5–10 W/min (Ramp) Cadence: >50 rpm Start: 25 W/2 min Effort: 12.5–25 W/2 min (Step) Cadence: 50–60 rpm Start: 25 W/2 min Effort: 12.5–25 W/2 min (step) Cadence: 50–60 rpm Naughton protocol (speed increment: 0.8 Km/h/3 min grade increment: 3.5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Ortega protocol (constant self selected speed, grade increment: 0–5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Modified Balke protocol (constant speed: 4.8 Km/h, grade increase: 1%/min)	1	10.8	1	HR <sub>peak</sub> >85% of predicted* RER <sub>peak</sub> >1.10, Borg ≥7	1	100%	–	1	–	134 (77%)	–
	IHM	MD, FSHD, LGMD, CMYo, CCD, NM, HMM Dystrophies, Myopathies	2	42 [25/17]	33.2 (2.3)	Warm-up: 0 W/1–3 min Start: 20–50 W/6 min Effort: 5–25 W/min (Ramp) Cadence: 60–80 rpm Warm-up: 5–15 W/min (Step) Cadence: 60 rpm Effort: 5–15 W/min (Step) Cadence: 60 rpm Warm-up: 0 W/2 min Effort: 3–20 W/min (Step) Cadence: 50–80 rpm Warm-up: 0 W/2 min Effort: 3–20 W/min (Ramp) Cadence: 60 rpm Warm-up: 0 W/1–3 min Effort: 5–10 W/min (Ramp) Cadence: >50 rpm Start: 25 W/2 min Effort: 12.5–25 W/2 min (Step) Cadence: 50–60 rpm Start: 25 W/2 min Effort: 12.5–25 W/2 min (step) Cadence: 50–60 rpm Naughton protocol (speed increment: 0.8 Km/h/3 min grade increment: 3.5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Ortega protocol (constant self selected speed, grade increment: 0–5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Modified Balke protocol (constant speed: 4.8 Km/h, grade increase: 1%/min)	2	13.9	1	HR <sub>peak</sub> >180 bpm or 85% of predicted; RER <sub>peak</sub> >1.00	2	100%	–	1	31.1 (68%)	158 (85%)	1.10
	IM	DM, PM	1	9 [2/7]	42.0 (3.0)	Warm-up: 5–15 W/min (Step) Cadence: 60 rpm Effort: 5–15 W/min (Step) Cadence: 60 rpm Warm-up: 0 W/2 min Effort: 3–20 W/min (Step) Cadence: 50–80 rpm Warm-up: 0 W/2 min Effort: 3–20 W/min (Ramp) Cadence: 60 rpm Warm-up: 0 W/1–3 min Effort: 5–10 W/min (Ramp) Cadence: >50 rpm Start: 25 W/2 min Effort: 12.5–25 W/2 min (Step) Cadence: 50–60 rpm Start: 25 W/2 min Effort: 12.5–25 W/2 min (step) Cadence: 50–60 rpm Naughton protocol (speed increment: 0.8 Km/h/3 min grade increment: 3.5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Ortega protocol (constant self selected speed, grade increment: 0–5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Modified Balke protocol (constant speed: 4.8 Km/h, grade increase: 1%/min)	–	–	–	–	1	100%	–	1	14.2 (33%)	127 (71%)	1.10
	MND	ALS, PPS	4	66 [42/24]	51.1 (8.3)	Warm-up: 0 W/2 min Effort: 3–20 W/min (Step) Cadence: 50–80 rpm Warm-up: 0 W/2 min Effort: 3–20 W/min (Ramp) Cadence: 60 rpm Warm-up: 0 W/1–3 min Effort: 5–10 W/min (Ramp) Cadence: >50 rpm Start: 25 W/2 min Effort: 12.5–25 W/2 min (Step) Cadence: 50–60 rpm Start: 25 W/2 min Effort: 12.5–25 W/2 min (step) Cadence: 50–60 rpm Naughton protocol (speed increment: 0.8 Km/h/3 min grade increment: 3.5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Ortega protocol (constant self selected speed, grade increment: 0–5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Modified Balke protocol (constant speed: 4.8 Km/h, grade increase: 1%/min)	1	8.0	–	–	2	100%	–	4	19.6 (49%)	138 (79%)	1.10
	PND	HMSN	1	18 [12/6]	49.0	Warm-up: 3–20 W/min (Ramp) Cadence: 60–80 rpm Warm-up: 0 W/1–3 min Effort: 5–10 W/min (Ramp) Cadence: >50 rpm Start: 25 W/2 min Effort: 12.5–25 W/2 min (Step) Cadence: 50–60 rpm Start: 25 W/2 min Effort: 12.5–25 W/2 min (step) Cadence: 50–60 rpm Naughton protocol (speed increment: 0.8 Km/h/3 min grade increment: 3.5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Ortega protocol (constant self selected speed, grade increment: 0–5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Modified Balke protocol (constant speed: 4.8 Km/h, grade increase: 1%/min)	1	10.8	1	HR <sub>peak</sub> >85% of predicted* RER <sub>peak</sub> >1.10, Borg ≥7	1	100%	–	1	–	133 (76%)	–
SRC	IHM	LGMD, MD	1	6 [4/2]	34.0 (5.0)	Start: 25 W/2 min Effort: 12.5–25 W/2 min (Step) Cadence: 50–60 rpm Start: 25 W/2 min Effort: 12.5–25 W/2 min (step) Cadence: 50–60 rpm Naughton protocol (speed increment: 0.8 Km/h/3 min grade increment: 3.5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Ortega protocol (constant self selected speed, grade increment: 0–5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Modified Balke protocol (constant speed: 4.8 Km/h, grade increase: 1%/min)	–	–	–	–	1	100%	–	1	17.1 (50%)	152 (82%)	–
	PND	HMSN	1	2 [0/2]	44.5	Cadence: 50–60 rpm Start: 25 W/2 min Effort: 12.5–25 W/2 min (step) Cadence: 50–60 rpm Naughton protocol (speed increment: 0.8 Km/h/3 min grade increment: 3.5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Ortega protocol (constant self selected speed, grade increment: 0–5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Modified Balke protocol (constant speed: 4.8 Km/h, grade increase: 1%/min)	–	–	–	–	1	100%	–	1	18.2 (43%)	164 (93%)	–
T	GSD	GSD II, V	2	10 [7/3]	51.7 (10.1)	Naughton protocol (speed increment: 0.8 Km/h/3 min grade increment: 3.5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Ortega protocol (constant self selected speed, grade increment: 0–5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Modified Balke protocol (constant speed: 4.8 Km/h, grade increase: 1%/min)	2	9.2	1	HR <sub>peak</sub> ≥85% of predicted; RER <sub>peak</sub> ≥1.11 75%	2	100%	–	2	19.6 (49%)	142 (82%)	0.97
	MitoD	*	2	27 [13/14]	30.8 (11.3)	Warm-up: 5–10 W/min (Step) or 20–30 W/2 min or 40 W/3 min Start: 20–50 W (6 min) Effort: 10–25 W/min (Ramp) Cadence: 60–80 rpm Warm-up: submaximal W/3–4 min or 20 W/1 min Effort: 5–20 W/min or 20–30 W/2 min (Step) Cadence: 50 rpm Warm-up: 0 W/4 min Effort: 5–25 W/min (Ramp) Cadence: 60–80 rpm Warm-up: 0 W/1–3 min Effort: 5–10 W/min (Ramp) Cadence: >50 rpm Start: 20–50 W/6 min Effort: 5–25 W/min (Ramp) Cadence: 60–80 rpm Warm-up: 5–15 W/min (Step) Cadence: 60 rpm Effort: 5–15 W/min (Step) Cadence: 60 rpm Warm-up: 0 W/2 min Effort: 3–20 W/min (Step) Cadence: 50–80 rpm Warm-up: 0 W/2 min Effort: 3–20 W/min (Ramp) Cadence: 60 rpm Warm-up: 0 W/1–3 min Effort: 5–10 W/min (Ramp) Cadence: >50 rpm Start: 25 W/2 min Effort: 12.5–25 W/2 min (Step) Cadence: 50–60 rpm Start: 25 W/2 min Effort: 12.5–25 W/2 min (step) Cadence: 50–60 rpm Naughton protocol (speed increment: 0.8 Km/h/3 min grade increment: 3.5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Ortega protocol (constant self selected speed, grade increment: 0–5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Modified Balke protocol (constant speed: 4.8 Km/h, grade increase: 1%/min)	1	10.0	–	–	2	100%	–	2	23.6 (50%)	167 (88%)	1.40
	PND	HMSN	1	1 [0/1]	51.0	Warm-up: 5–10 W/min (Step) or 20–30 W/2 min or 40 W/3 min Start: 20–50 W (6 min) Effort: 10–25 W/min (Ramp) Cadence: 60–80 rpm Warm-up: submaximal W/3–4 min or 20 W/1 min Effort: 5–20 W/min or 20–30 W/2 min (Step) Cadence: 50 rpm Warm-up: 0 W/4 min Effort: 5–25 W/min (Ramp) Cadence: 60–80 rpm Warm-up: 0 W/1–3 min Effort: 5–10 W/min (Ramp) Cadence: >50 rpm Start: 20–50 W/6 min Effort: 5–25 W/min (Ramp) Cadence: 60–80 rpm Warm-up: 5–15 W/min (Step) Cadence: 60 rpm Effort: 5–15 W/min (Step) Cadence: 60 rpm Warm-up: 0 W/2 min Effort: 3–20 W/min (Step) Cadence: 50–80 rpm Warm-up: 0 W/2 min Effort: 3–20 W/min (Ramp) Cadence: 60 rpm Warm-up: 0 W/1–3 min Effort: 5–10 W/min (Ramp) Cadence: >50 rpm Start: 25 W/2 min Effort: 12.5–25 W/2 min (Step) Cadence: 50–60 rpm Start: 25 W/2 min Effort: 12.5–25 W/2 min (step) Cadence: 50–60 rpm Naughton protocol (speed increment: 0.8 Km/h/3 min grade increment: 3.5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Ortega protocol (constant self selected speed, grade increment: 0–5%/3 min) Bruce protocol (speed increment: 2.7 Km/h, grade increment: 2%/3 min) Modified Balke protocol (constant speed: 4.8 Km/h, grade increase: 1%/min)	1	25.0	–	–	1	100%	–	1	30.0 (71%)	–	–

Legend: UPC: upright cycle ergometer; RC: recumbent cycle ergometer; SRC: semi-recumbent cycle ergometer; T: treadmill; AC: arm-crank ergometer; GSD: glycogen storage disorders; MitoD: mitochondrial disorders; IHM: inherited myopathies; IM: inflammatory myopathies; PND: peripheral nerve disorders; NMJD: neuromuscular junction disorders; CM: cardiomyopathy; MELAS: mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes; PEO: progressive external ophthalmoplegia; RRFD: ragged red fiber disease; CPTD: carnitine palmitoyl transferase deficiency; MD: myotonic dystrophy; FSHD: facioscapulohumeral muscular dystrophy; LGMD: limb-girdle muscular dystrophy; CMYo: congenital myopathy; CCD: central core disease; NM: nemaline myopathy; HMM: hereditary myosin myopathy; MS: multiple sclerosis; DM: dermatomyositis; ALS: amyotrophic lateral sclerosis; PPS: post-polio syndrome; SMA: spinal muscular atrophy; MG: myasthenia gravis; HMSN: hereditary motor and sensory neuropathy; n: number; m: male; f: female; SD: standard deviation; -: not reported; \*: not specified.

Table 10. Characteristic of the studies with sufficient score in the ATS/ACCP adapted quality list – Pediatric.

Exercise Modality	NMD sub classification	Disease	Studies (n)	Patients (n)	Age (Mean-SD)	Protocol	Quality			Feasibility		Aerobic fitness					
							Studies (n)	Duration (min)	Studies (n)	Criteria of maximal effort	Studies (n)	Completion rate	Adverse event	Studies (n)	VO <sub>2peak</sub> (%) pred)	HR <sub>peak</sub> (%)pred)	RER <sub>peak</sub>
UPC	MitoD	MCAD, SCAD, MADD	1	4 [2/2]	15 (5.1)	Warm-up: 0 W/2 min Effort: 5–20 W/min (Ramp)	–	–	–	1	100%	–	1	–	185 (94%)	1.16	
	IHM	DMD, BMD	1	9 [9/0]	10.3 (4.7)	Warm-up: 0 W/1-2 min Effort: 5–10 W/min (Ramp)	1	8.3	1	HR <sub>peak</sub> >180 bpm RER <sub>peak</sub> ≥1.00 1%	1	100%	–	1	25.2 (51%)	156 (79%)	1.10
	IM	JDM	5	66 [24/26]	12.3 (3.7)	Warm-up: 0 W/1-3 min Effort: 10–20 W/min (Ramp) Cadence:>60-80rpm	1	8.1	1	RER <sub>peak</sub> >1.10 91%	5	100%	–	3	25.3 (51%)	176 (90%)	1.14
T	IM	JDM	2	41 [15/26]	11.2 (1.0)	Modified Dubowy (speed increment: 0.5 Km/h, grade increment: 3%/1.5 min) Bruce protocol (speed increment: 1.3–1.5 Km/h, grade increment: 2%/3 min)	2	9.3	1	HR <sub>peak</sub> >180 bpmRER <sub>peak</sub> ≥1.00 67%	–	–	–	2	34.1 (68%)	184 (92%)	1.05

Legend: UPC: upright cycle ergometer; RC: recumbent cycle ergometer; SC: semi-recumbent cycle ergometer; T: treadmill; GSD: glycogen storage disorders; MitoD: mitochondrial disorders; IHM: inherited myopathies; IM: inflammatory myopathies; MCAD: medium-chain Acyl CoA; SCAD: short-chain Acyl CoA dehydrogenase deficiency; MADD: Multiple AcylCoA dehydrogenase deficiency; DMD: duchenne muscular dystrophy; BMD: becker muscular dystrophy; JDM: juvenile dermatomyositis; n: number; m: male; f: female; SD: standard deviation; -: not reported; n: number of articles; m: male; f: female; SD: standard deviation; -: not reported.

dicted VO<sub>2peak</sub>) on the treadmill (Table 8). Moreover, adult patients with glycogen storage disorders, mitochondrial disorders and inflammatory myopathies, and pediatric patients with inherited myopathies and inflammatory myopathies showed a VO<sub>2peak</sub> below 50% of the predicted value in the upright cycle ergometer (Tables 7 and 8).

The highest percentages of the HR<sub>peak</sub> (≥90% of the predicted value) for the adult population were found using the treadmill for patients with glycogen storage disorders, mitochondrial disorders and inflammatory myopathies. For cycle ergometry, normal values of the HR<sub>peak</sub> were observed in patients with inherited myopathies on the semi-recumbent cycle ergometer, and in patients with a mix of diseases on the upright cycle ergometer (93% of the predicted value). In children/adolescents, only patients with glycogen storage disorders on the upright cycle ergometer showed an HR<sub>peak</sub> ≥95% of the predicted value. As expected, low values of the respiratory exchange ratio (RER<sub>peak</sub> <1.1 in adults and <1.0 in children/adolescents) were observed in patients with glycogen storage disorders using the upright cycle ergometer (RER<sub>peak</sub> = 1.0) and treadmill (RER<sub>peak</sub> = 0.9–0.8) (Tables 7 and 8). Adult patients with motor neuron disease using the recumbent cycle ergometer and the arm-crank also showed low RER<sub>peak</sub> values (Table 7).

### 3.7. Methodological quality

The methodological quality of the included studies varied. In the adult population, 17 studies (28%) that used the upright cycle ergometer and four studies (40%) that used the treadmill demonstrated respectively sufficient (upright cycle ergometer = 16; treadmill = 3) [8,26,28,30,34,42,44,45,52, \_

58,59,73,75,80,83,93,97,98] and moderate (upright cycle ergometer = 1; treadmill = 1) [9,25] methodological quality. One study using the semi-recumbent cycle ergometer had moderate methodological quality [46]. However, no studies achieved a high methodological quality. In children and adolescents, seven studies (50%) using the upright cycle ergometer [66–69,101,102,106] and two studies (40%) using the treadmill [62,105] demonstrated sufficient methodological quality (Supplementary Material D).

### 3.8. Data syntheses

Tables 9 and 10 summarize the protocol, quality of test performance, feasibility, and aerobic fitness from the 30 studies (one study used two exercise modalities) with sufficient-to-moderate methodological quality. From these studies, 10 presented information about the quality of the test performance, including test duration [8,9,34,42,62,66,68,75,93,105] and the number of patients reaching maximal effort [8,9,25,44,58,59,62,66,68,98]; over 25 studies reported feasibility or aerobic fitness details (n = 27 and 26 studies, respectively) [8,9,25,26,28,30,34,42,44,45,52,58,59,62,65–69,73,75,80,83,84,93,97,98,102,105,106].

Excellent feasibility with a completion rate of 100% and low aerobic fitness (<80% of the predicted VO<sub>2peak</sub>) were found in those studies. However, a high quality of test performance, mainly for maximal effort, was only observed in six studies

[8,9,44,62,66,68]. The best evidence of CPET protocols was based on these studies with a higher quality of test performance and feasibility. In this regard, the upright cycle ergometer is recommended to assess most subtypes of ambulatory adults with NMDs and some ambulatory pediatric patients. The ramp protocol and individualized work increments are advisable for both populations, but different workloads are suggested for adults and pediatric patients. The level of functional capacity [8] or physical fitness of the adult patients [44] can guide the rater to select the best workload from 5 to 25 W/min. For pediatric patients, the distance covered during the six-minute walking test (6MWT) might help to select workloads from 5 to 15 W/min [66]. The treadmill can be used to assess ambulatory adults using the Naughton protocol [9], and children and adolescents with the Bruce protocol [62].

#### 4. Discussion

Ninety-two studies (A, 74; P, 18) using CPET to assess patients with NMDs were included in this systematic review and evaluated on the quality of test performance, feasibility and methodological quality. Only 30 studies (A, 21; P, 9) met sufficient-to-moderate methodological quality according to the ATS/ACCP recommendations. However, from those, only six studies (A, 3; P, 3) were included in the best evidence synthesis of CPET protocols for patients with NMDs regarding excellent feasibility and quality of test performance.

##### 4.1. Methodological quality

The main reasons for the low scores of the studies in the methodological quality checklist regard failure in reporting methodological information, such as calibration, monitoring measurements, for example, blood pressure and oxygen saturation, and performing pretest procedures such as pulmonary function tests. Not following the ATS/ACCP recommendations [6] in performing and reporting CPET may compromise the study's reproducibility and credibility, as well as the patients' safety and performance during the test. Problems in calibration may generate unreliable CPET outcomes, while abnormalities in blood pressure and saturation are primary relative and absolute indications for terminating the test [24,29]. Moreover, since some patients with NMDs present with respiratory muscle weakness, a pulmonary function test can help to identify a pulmonary limitation during exercise [8,110]. Therefore, to increase the body of evidence for the applicability of CPET in NMD, future studies should apply the methodological quality checklist of the ATS/ACCP in the design and report of CPET in NMDs.

##### 4.2. Characteristics of the CPET

The upright cycle ergometer was the most frequently used device for assessing various adult and pediatric patients with NMD. Our findings agree with those of other systematic reviews of CPET for healthy, oncologic, and neurologic patients [111–113]. For clinical situations, the upright cycle ergometers are recommended over treadmills, due to their safety, less need for coordination and balance, easy measurement, and better

quality of monitoring physiological variables [5,6]. A step protocol with individualized increments was the most frequently used for assessing adults patients with NMDs in the studies with sufficient methodological quality. However, a ramp protocol was selected in the included studies that presented the best evidence synthesis for the adult population, regarding excellent feasibility and quality of test performance [8,44]. A ramp protocol is advisable for use in patients with NMDs, because it has a linear increase of workload allowing slight metabolic changes and neuromuscular recruitment through the CPET [114]. In agreement with this, most studies assessing pediatric patients used a ramp protocol.

For this type of protocol, workload increments from 5 to 25 W/min were prevalent in the studies, with sufficient-to-moderate methodological quality and the best evidence synthesis assessing adult patients. In the pediatric population, the workload steps varied from 5 to 20 W/min. Earlier fatigue will occur in more intense workload steps. Therefore, the workload steps should be selected carefully, using the level of functional capacity [8] or aerobic fitness of the patients [44]. The six-minute walking test (6MWT) for example, might be a good option for screening the functional capacity of the patient before the CPET [66].

When an upright cycle ergometer is not available, a treadmill might be an alternative option for assessing aerobic fitness in some subtypes of NMDs. It was the second most frequently used device in the included studies and in those included in the best evidence synthesis [9,62]. The Naughton and the Bruce protocols offered the best evidence for respectively assessing adults and pediatric patients [9,62]. The Bruce protocol is a frequently used protocol [115]; however, it has some disadvantages when assessing children and adolescents with reduced functional capacity. The primary disadvantage is posed by the large and unequal increments that impact the obtained exercise response [115], and a secondary disadvantage is the high metabolic demand in the first stages, requiring an oxygen cost of 17.5 ml/kg/min (5 METS), which represents more than 60% of the mean  $\text{VO}_{2\text{peak}}$  achieved by the young NMD patients on the treadmill. Therefore, the Dubowy protocol, with small and even increments (speed increment: 0.5 km/hr and grade: 3% each 1.5 minute), is more advisable for assessing aerobic fitness in children and adolescents with NMDs.

##### 4.3. Quality of test performance

The recommended test duration was met in the CPET protocols used in all studies with sufficient methodological quality, suggesting that the work rate selected might be appropriated for terminating the CPET in 8–12 minutes, without early termination due to localized muscular fatigue, and low stress of the cardiopulmonary system [5]. However, even in the studies with high methodological quality, few patients performed a maximal CPET regarding the objective criteria ( $\text{HR}_{\text{peak}}$  and  $\text{RER}_{\text{peak}}$ ), applied when a plateau in the  $\text{VO}_{2\text{peak}}$  is not observed [116].

In general, we found a reduced  $\text{HR}_{\text{peak}}$  and  $\text{RER}_{\text{peak}}$  within the minimum established limits (1.0 and 1.1) for most



subtypes of NMDs. When muscle metabolism is the primary limiting factor of the CPET, a low  $HR_{peak}$  is expected, because exercise ends before maximally stressing the cardiovascular system [7,116]. Involvement of the components of the motor unit (one or more) and some structures related to energy production cause changes in the muscle structure and metabolism of patients with NMDs [15,117]. This impacts the oxygen conduction and use by the active muscles [7,44], and helps to explain the observed low  $HR_{peak}$ . Moreover, this suggests that the  $HR_{peak}$  may not be a good quality criterion by which to assess maximal performance in patients with NMDs.

#### 4.4. Feasibility of CPET

A high completion rate and few adverse events and complications were found in the studies with sufficient methodological quality, indicating excellent feasibility of the CPET protocols for ambulatory patients with NMDs. The feasibility of CPET was also evaluated for other clinical groups, such as adults with multiple sclerosis, advanced cancer [113,118], and children with pulmonary hypertension [119]. In these studies, as observed in the present review, the feasibility of CPET was limited to patients with high physical abilities. Therefore, in order to make CPET part of the daily clinical evaluation of patients with NMDs, the clinician must consider the functional level of patients when selecting the exercise modality. Moreover, less commonly used devices, such as arm-crank ergometers and treadmills with body weight support, can be alternatives by which to assess patients with reduced physical abilities [120–122]. Another relevant aspect of the feasibility of CPET is the patient's ability to follow the rater instructions because. Some patients with NMD may exhibit cognitive impairments. A reduced understanding of commands during the CPET may compromise the patient's motivation and, consequently, his or her performance.

#### 4.5. Aerobic fitness in NMD patients

In general, patients with NMDs assessed in the included studies presented with reduced aerobic fitness. The low  $VO_{2peak}$  may result from anything that changes the pathway of oxygen uptake, extraction or use by the active muscle. Although cardiac or pulmonary diseases cannot be ruled out, the low  $VO_{2peak}$  can be primarily explained by the limited capacity of the muscles to extract and use oxygen during exercise (muscle metabolism limitation), associated with a mitochondrial defect and the effect of deconditioning due to a sedentary lifestyle [8,44].

Additionally, heterogeneous percentages of the predicted  $VO_{2peak}$  were observed in patients with the same subtypes of NMDs who performed the CPET in diverse exercise modalities. Most adults, for example, had a higher predicted  $VO_{2peak}$  on the treadmill as compared to the upright cycle ergometer; with the exception of patients with motor neuron diseases. This finding agrees with the observation in healthy subjects that shows a 5–10% higher  $VO_{2peak}$  on the treadmill [6]. Indeed, walking on a treadmill activates a higher muscle

mass and requires a higher metabolic cost to support the body weight against gravity than does the cycling ergometer [6]. The opposite finding for patients with motor neuron diseases in these devices can be justified by the functional level of the assessed patients who are able to walk on the treadmill with or without hand support [82]. Holding the treadmill handrail while walking affects the metabolic demand of the task, reducing the  $VO_{2peak}$  [6].

Pediatric patients also showed a different predicted  $VO_{2peak}$  between the diverse devices. In glycogen storage disorders, for example, a higher  $VO_{2peak}$  was found using the upright cycle ergometer as compared to the treadmill. However, it is important to notice that the CPET results in the upright cycle ergometer were only based on one patient [104]. Surprisingly, young patients with inflammatory myopathies had a higher predicted  $VO_{2peak}$  in the CPET using a supine cycle ergometer as compared to the treadmill. Nevertheless, only patients in disease remission composed the study using the supine cycle ergometer, while younger patients and patients with both active disease and disease remission composed the studies using the treadmill [62,104,105,107]. Submaximal CPET outcomes were shown for younger inflammatory myopathy patients with active disease [62].

### 5. General recommendations for CPET in NMDs

We advise clinicians to use the upright cycle ergometer as the primary exercise modality to assess ambulatory patients with NMDs. The ramp-wise protocol with workload selection based on the patient's functional capacity and aerobic fitness (5 to 25 W/min for adults and 5 to 20 W/min for young patients with NMDs) is also suggested for this device. Prior to the assessment of a CPET, we recommend that the patient receives a thorough cardiovascular screening. During the CPET, the use of additional measurements in addition to the gas exchange, for example, baseline pulmonary function test, 12-lead electrocardiogram, saturation, and blood pressure monitoring. Most NMDs might have asymptomatic cardiac diseases, and these measures help to guarantee the patient's safety during the performance of a CPET. Moreover when assessing the quality of CPET performed, we suggest to consider the  $RER_{peak}$  as the principal physiological variable to classify the patient's delivered effort.

### 6. Conclusion

The knowledge about exercise limiting factors and aerobic fitness in NMDs is increasing and brings the need to understand the applicability and safety of the gold-standard method, CPET, in assessing these variables for this specific group. Our results indicate that CPET is feasible for adult and young patients with NMDs when the patient's functional level and the exercise modality of CPET are taken into account. However, to safely implement CPET in the routine assessment of patients with NMDs, clinicians are urged to follow the ATS/ACCP recommendations for performing and reporting CPET. Furthermore, there is a vast potential for standardization and design of disease-specific CPET protocols for patients with NMDs.



## 7. Expert opinion

From the results of this systematic review, we provide information about the best-evidence synthesis of CPET protocols and their feasibility for ambulatory patients with NMDs. Understanding the best-evidence for incremental protocol design and work rate increment is fundamental for clinicians to test the metabolic and exercise responses without generating early-localized peripheral fatigue. Nevertheless, future studies should assess the applicability of timed tests, such as the six-minute walking test, in screening the functional capacity of the patients and in the guidance for workload selection.

Even though our results suggest that CPET is feasible for ambulatory patients, the low adherence of the included studies to the ATS/ACCP recommendations and the wide variety of available protocols indicate a need for standardization in performing and reporting CPET for this group. However, it is important to highlight that the reports of the included studies limited our assumptions. Perhaps more patients did not complete the CPET and thereby were excluded from the final sample and not reported in the studies, or perhaps more authors followed the recommended procedures from the ATS/ACCP guidelines but did not report this in the publications. Moreover, there is no information available regarding the feasibility of CPET for non-ambulatory patients. Future studies are urged to fill this gap. Novel devices, such as the lower body positive support treadmills, might offer an alternative and should be explored in the design of specific CPET protocols for less functional patients.

For many years, exercise has been a stigma for patients with NMDs, due to the theoretical concept that weak muscles work near their maximal limit. Leading health professionals did therefore not recommend exercise for this group. Despite this uncertainty, safety was an under-investigated aspect for CPET in this group. The analysis of safety (bio)markers, such as the CPK level and the rating of perceived muscle hurt before and after CPETs, would encourage CPET use for some progressive NMDs and NMDs associated with cardiomyopathy.

The reduced aerobic fitness of patients with NMDs is another alarming observation from this systematic review. For the healthy and chronically impaired populations, a low aerobic fitness indicates a high risk of morbidity and mortality. Exercise training programmes have great potential in dealing with the harmful effects of reduced physical activity and low aerobic fitness. Most clinical trials included in this review used CPET to prescribe training intensity and to assess its efficacy. Therefore, improvements in CPET protocols for ambulatory and non-ambulatory patients might favor the implementation of CPET in the routine assessment of patients with NMDs, for prescribing individual exercise training intensity and assessing the efficacy of an intervention, thereby boosting the development of the first exercise training guidelines for this group.

Finally, our results also suggest that the existing objective criteria of maximal effort should be revised for patients with NMDs, because their muscle metabolism limits the achievement of  $HR_{peak}$ . Other CPET variables, such as anaerobic threshold (AT), oxygen uptake efficiency slope (OUES), and the relation between oxygen uptake and work rate ( $\Delta VO_2/\Delta WR$ ), should be better explored in future studies.

## Acknowledgments

The authors wish to thank FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo).

## Funding

This paper was funded by FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo; Process number: 2019/22718-7).

## Declaration of interest

BB obtained research grants from Prinses Beatrix Spierfonds and Stichting Spieren voor Spieren, both non-profit foundations. His employer receives fees for SMA-related consultancy activities. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

## Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

## ORCID

Gabriela Barroso de Queiroz Davoli  <http://orcid.org/0000-0002-4981-3868>

Bart Bartels  <http://orcid.org/0000-0002-5801-6692>

Ana Claudia Mattiello-Sverzut  <http://orcid.org/0000-0002-4181-0718>

Tim Takken  <http://orcid.org/0000-0002-7737-118X>

## References

Papers of special note have been highlighted as either of interest (\*) or of considerable interest (\*\*) to readers.

1. Dowling JJ, D Gonorazky H, Rd C, et al. Treating pediatric neuromuscular disorders: the future is now. *Am J Med Genet A*. 2018;176(4):804–841.
2. Darin N, Tulinius M. Neuromuscular disorders in childhood: a descriptive epidemiological study from western Sweden. *Neuromuscul Disord*. 2000;10(1):1–9.
3. Anziska Y, Sternberg A. Exercise in neuromuscular disease. *Muscle Nerve*. 2013;48(1):3–20.
4. Allen HD, Thrush PT, Hoffman TM, et al. Cardiac management in neuromuscular diseases. *Phys Med Rehabil Clin N Am*. 2012;23(4):855–868.
5. Tran D. Cardiopulmonary Exercise Testing. *Methods Mol Biol*. 2018;1735:285–295.
6. American Thoracic Society; American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. *Am J Respir Crit Care Med*. 2003;167(2): 211–277.
7. Van Brussel M, Bongers BC, Hulzebos EHJ, et al. A systematic approach to interpreting the cardiopulmonary exercise test in pediatrics. *Pediatr Exerc Sci*. 2019;31(2):194–203. • **Of interest: Provides evidence of CPET outcomes interpretation**
8. Rapin A, Etossé A, Tambosco L, et al. Aerobic capacities and exercise tolerance in neuromuscular diseases: a descriptive study. *Ann Phys Rehabil Med*. 2013;56(6):420–433. •• **Of considerable interest: Provides an evidence-based presentation of CPET protocol for adult patients with NMDs**
9. Crescimanno G, Modica R, Lo Mauro R, et al. Role of the cardio-pulmonary exercise test and six-minute walking test in the evaluation of exercise performance in patients with late-onset

- Pompe disease. *Neuromuscul Disord.* 2015;25(7):542–547. **Of considerable interest: Provides an evidence-based presentation of CPET protocol for adult patients with NMDs**
10. Wiesinger GF, Quittan M, Aringer M, et al. Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. *Br J Rheumatol.* 1998;37(2):196–200.
  11. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* 2009 Jul 21;6(7):e1000097.
  12. Bramer WM, de Jonge GB, Rethlefsen ML, et al. A systematic approach to searching: an efficient and complete method to develop literature searches. *J Med Libr Assoc.* 2018;106(4):531–541.
  13. van der Steeg GE, Takken T. Reference values for maximum oxygen uptake relative to body mass in Dutch/Flemish subjects aged 6–65 years: the lowlands fitness registry. *Eur J Appl Physiol.* 2021 Feb 1;121(4):1189–1196.
  14. Tanaka H, Monahan KD, Seals DR. Age-predicted maximal heart rate revisited. *J Am Coll Cardiol.* 2001;37(1):153–156.
  15. Duboway KO, Baden W, Bernitzki S, et al. A practical and transferable new protocol for treadmill testing of children and adults. *Cardiol Young.* 2008;18(6):615–623.
  16. Naughton J, Balke B, Nagle F. Refinements in method of evaluation and physical conditioning before and after myocardial infarction. *Am J Cardiol.* 1964;14:837–843.
  17. Bruce RA, Blackmon JR, Jones JW, et al. Exercising testing in adult normal subjects and cardiac patients. *Pediatrics.* 1963;32(SUPPL):742–756.
  18. Balke B, Ware RW. An experimental study of physical fitness of Air Force personnel. *U S Armed Forces Med J.* 1959;10(6):675–688.
  19. Anziska Y, Inan S. Exercise in neuromuscular disease. *Semin Neurol.* 2014;34(5):542–556.
  20. Dandurand RJ, Matthews PM, Arnold DL, et al. Mitochondrial disease. Pulmonary function, exercise performance, and blood lactate levels. *Chest.* 1995;108(1):182–189.
  21. Wiesinger GF, Quittan M, Nuhr M, et al. Aerobic capacity in adult dermatomyositis/polymyositis patients and healthy controls. *Arch Phys Med Rehabil.* 2000;81(1):1–5.
  22. Carroll JE, Hagberg JM, Brooke MH, et al. Bicycle ergometry and gas exchange measurements in neuromuscular diseases. *Arch Neurol.* 1979;36(8):457–461.
  23. Mezzani A, Pisano F, Cavalli A, et al. Reduced exercise capacity in early-stage amyotrophic lateral sclerosis: role of skeletal muscle. *Amyotroph Lateral Scler.* 2012;13(1):87–94.
  24. Sanjak M, Paulson D, Sufit R, et al. Physiologic and metabolic response to progressive and prolonged exercise in amyotrophic lateral sclerosis. *Neurology.* 1987;37(7):1217–1220.
  25. Weinstein AA, Drinkard BM, Diao G, et al. Exploratory analysis of the relationships between aerobic capacity and self-reported fatigue in patients with rheumatoid arthritis, polymyositis, and chronic fatigue syndrome. *PM R.* 2009;1(7):620–628.
  26. Willén C, Cider A, Sunnerhagen KS. Physical performance in individuals with late effects of polio. *Scand J Rehabil Med.* 1999;31(4):244–249.
  27. Gimenes AC, Neder JA, Dal Corso S, et al. Relationship between work rate and oxygen uptake in mitochondrial myopathy during ramp-incremental exercise. *Braz J Med Biol Res.* 2011;44(4):354–360.
  28. Heinicke K, Taivassalo T, Wyrick P, et al. Exertional dyspnea in mitochondrial myopathy: clinical features and physiological mechanisms. *Am J Physiol Regul Integr Comp Physiol.* 2011;301(4):R873–84.
  29. Hooper RG, Thomas AR, Kearn RA. Mitochondrial enzyme deficiency causing exercise limitation in normal-appearing adults. *Chest.* 1995;107(2):317–322. PMID: 7842754
  30. O'Dochartaigh CS, Ong HY, Lovell SM, et al. Oxygen consumption is increased relative to work rate in patients with McArdle's disease. *Eur J Clin Invest.* 2004;34(11):731–737.
  31. Taivassalo T, Jensen TD, Kennaway N, et al. The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patients. *Brain.* 2003;126(Pt 2):413–423.
  32. Al-Rahamneh HQ, Faulkner JA, Byrne C, et al. Relationship between perceived exertion and physiologic markers during arm exercise with able-bodied participants and participants with poliomyelitis. *Arch Phys Med Rehabil.* 2010;91(2):273–277.
  33. Fernández J, Montemayor T, Bautista J, et al. Utilidad de la prueba de ejercicio cardiopulmonar en pacientes con miopatía mitocondrial [The use of cardiopulmonary exercise test in patients with mitochondrial myopathies]. *Med Clin (Barc).* 2000;114(4):121–127. Spanish.
  34. Flaherty KR, Wald J, Weisman IM, et al. Unexplained exertional limitation: characterization of patients with a mitochondrial myopathy. *Am J Respir Crit Care Med.* 2001;164(3):425–432.
  35. Paterson DJ, Friedland JS, Bascom DA, et al. Changes in arterial K<sup>+</sup> and ventilation during exercise in normal subjects and subjects with McArdle's syndrome. *J Physiol.* 1990;429(1):339–348.
  36. Silva HCA, Leite JJ, Carvalho MS, et al. Teste de esforço cardiopulmonar na avaliação de doenças musculares. *Arq Neuro Psiquiatr. online.* 1998;56(2):258–266.
  37. Berntsen KS, Edvardsen E, Hansen BH, et al. Cardiorespiratory fitness in long-term juvenile dermatomyositis: a controlled, cross-sectional study of active/inactive disease. *Rheumatology (Oxford).* 2019;58(3):492–501.
  38. Bogaard JM, Scholte HR, Busch HF, et al. Anaerobic threshold as detected from ventilatory and metabolic exercise responses in patients with mitochondrial respiratory chain defect. *Adv Cardiol.* 1986;35:135–145.
  39. Bogaard JM, Busch HF, Scholte HR, et al. Exercise responses in patients with an enzyme deficiency in the mitochondrial respiratory chain. *Eur Respir J.* 1988;1(5):445–452. PMID: 3139446
  40. Bravo DM, Gimenes AC, Nascimento RB, et al. Skeletal muscle reoxygenation after high-intensity exercise in mitochondrial myopathy. *Eur J Appl Physiol.* 2012;112(5):1763–1771. Epub 2011 Sep 4
  41. Delaney NF, Sharma R, Tadvalkar L, et al. Metabolic profiles of exercise in patients with McArdle disease or mitochondrial myopathy. *Proc Natl Acad Sci U S A.* 2017;114(31):8402–8407. Epub 2017 Jul 17
  42. Elliot DL, Buist NR, Goldberg L, et al. Metabolic myopathies: evaluation by graded exercise testing. *Medicine (Baltimore).* 1989;68(3):163–172. PMID: 2716515.
  43. Gourcerol D, Bergoin C, Thirard L, et al. Intérêt de l'épreuve fonctionnelle d'exercice au cours des myopathies inflammatoires avec atteinte pulmonaire [Functional exercise testing in idiopathic inflammatory myopathies with pulmonary involvement]. *Rev Mal Respir.* 2008;25(1):13–21. French.
  44. Grassi B, Marzorati M, Lanfranconi F, et al. Impaired oxygen extraction in metabolic myopathies: detection and quantification by near-infrared spectroscopy. *Muscle Nerve.* 2007;35(4):510–520. **Of considerable interest: Provides an evidence-based presentation of CPET protocol for adult patients with NMDs**
  45. Fernández GJ, Montemayor RJ, Bautista LJ, et al. Exactitud y validez del umbral láctico frente a otros métodos no invasivos de medición del umbral anaerobio en pacientes con miopatías metabólicas [Accuracy and validity of the lactic threshold compared to other noninvasive methods of measuring the anaerobic threshold in patients with metabolic myopathies]. *Arch Bronconeumol.* 1996;32(4):176–182. Spanish.
  46. Hagberg JM, King DS, Rogers MA, et al. Exercise and recovery ventilatory and VO<sub>2</sub> responses of patients with McArdle's disease. *J Appl Physiol* (1985). 1990;68(4):1393–1398.
  47. Hagberg JM, Coyle EF, Carroll JE, et al. Exercise hyperventilation in patients with McArdle's disease. *J Appl Physiol Respir Environ Exerc Physiol.* 1982;52(4):991–994.
  48. Hebert CA, Byrnes TJ, Baethge BA, et al. Exercise limitation in patients with polymyositis. *Chest.* 1990;98(2):352–357.
  49. Jeppesen TD, Quistorff B, Wibrand F, et al. 31P-MRS of skeletal muscle is not a sensitive diagnostic test for mitochondrial myopathy. *J Neurol.* 2007;254(1):29–37.
  50. Jeppesen TD, Olsen D, Vissing J. Cycle ergometry is not a sensitive diagnostic test for mitochondrial myopathy. *J Neurol.* 2003;250(3):293–299.

51. Jeppesen TD, Schwartz M, Olsen DB, et al. Oxidative capacity correlates with muscle mutation load in mitochondrial myopathy. *Ann Neurol*. 2003;54(1):86–92.
52. Lindholm H, Löfberg M, Somer H, et al. Abnormal blood lactate accumulation after exercise in patients with multiple mitochondrial DNA deletions and minor muscular symptoms. *Clin Physiol Funct Imaging*. 2004;24(2):109–115.
53. Noury JB, Zagnoli F, Carré JL, et al. Exercise testing-based algorithms to diagnose McArdle disease and MAD defects. *Acta Neurol Scand*. 2018;138(4):301–307.
54. Ong HY, O'Dochartaigh CS, Lovell S, et al. Gas exchange responses to constant work-rate exercise in patients with glycogenosis type V and VII. *Am J Respir Crit Care Med*. 2004;169(11):1238–1244.
55. Piirilä P, Similä ME, Palmio J, et al. Unique exercise lactate profile in muscle Phosphofructokinase Deficiency (Tarui Disease); Difference Compared with McArdle Disease. *Front Neurol*. 2016;7:82.
56. Rannou F, Uguen A, Scotet V, et al. diagnostic algorithm for glycogenoses and myoadenylate deaminase deficiency based on exercise testing parameters: A prospective study. *PLoS One*. 2015;10(7):e0132972.
57. Riley M, Nicholls DP, Nugent AM, et al. Respiratory gas exchange and metabolic responses during exercise in McArdle's disease. *J Appl Physiol* (1985). 1993;75(2):745–754.
58. Roef MJ, Kalhan SC, Reijngoud DJ, et al. Lactate disposal via gluconeogenesis is increased during exercise in patients with mitochondrial myopathy due to complex I deficiency. *Pediatr Res*. 2002;51(5):592–597.
59. Roef MJ, Reijngoud DJ, Jeneson JA, et al. Resting oxygen consumption and in vivo ADP are increased in myopathy due to complex I deficiency. *Neurology*. 2002 Apr 9;58(7):1088–1093. PMID: 11940698
60. Sperfeld A, Vietzke G, Kleber FX, et al. Die Spiroergometrie in der diagnostik mitochondrialer erkrankungen [Cardio-pulmonary exercise testing as a screening method in mitochondrial disorders]. *Nervenarzt*. 1999;70(2):155–161. German.
61. Ylikallio E, Auranen M, Mahjneh I, et al. decreased aerobic capacity in ANO5-muscular dystrophy. *J Neuromuscul Dis*. 2016;3(4):475–485.
62. Takken T, Spermon N, Helders PJ, et al. Aerobic exercise capacity in patients with juvenile dermatomyositis. *J Rheumatol*. 2003;30(5):1075–1080. PMID: 12734909. **Of considerable interest: Provides an evidence-based presentation of CPET protocol for pediatric patients with NMDs**
63. Sockolov R, Irwin B, Dressendorfer RH, et al. Exercise performance in 6-to-11-year-old boys with Duchenne muscular dystrophy. *Arch Phys Med Rehabil*. 1977;58(5):195–201. PMID: 851390
64. Takken T, Elst E, Spermon N, et al. The physiological and physical determinants of functional ability measures in children with juvenile dermatomyositis. *Rheumatology (Oxford)*. 2003;42(4):591–595.
65. Takken T, van der Net J, Helders PJ. The reliability of an aerobic and an anaerobic exercise tolerance test in patients with juvenile onset dermatomyositis. *J Rheumatol*. 2005;32(4):734–739. PMID: 15801033
66. Bartels B, Takken T, Blank AC, et al. cardiopulmonary exercise testing in children and adolescents with dystrophinopathies: A pilot study. *Pediatr Phys Ther*. 2015;27(3):227–234. **Of considerable interest: Provides an evidence-based presentation of CPET protocol for pediatric patients with NMDs**
67. Habers GE, De Knikker R, Van Brussel M, et al. Near-infrared spectroscopy during exercise and recovery in children with juvenile dermatomyositis. *Muscle Nerve*. 2013;47(1):108–115.
68. Hicks JE, Drinkard B, Summers RM, et al. Decreased aerobic capacity in children with juvenile dermatomyositis. *Arthritis Rheum*. 2002;47(2):118–123. **Of considerable interest: Provides an evidence-based presentation of CPET protocol for pediatric patients with NMDs**
69. Groen WG, Hulzebos HJ, Helders PJ, et al. Oxygen uptake to work rate slope in children with a heart, lung or muscle disease. *Int J Sports Med*. 2010;31(3):202–206.
70. van Brussel M, van Oorschot JW, Schmitz JP, et al. muscle metabolic responses during dynamic in-magnet exercise testing: A pilot study in children with an idiopathic inflammatory myopathy. *Acad Radiol*. 2015;22(11):1443–1448.
71. Drinkard BE, Hicks J, Danoff J, et al. Fitness as a determinant of the oxygen uptake/work rate slope in healthy children and children with inflammatory myopathy. *Can J Appl Physiol*. 2003;28(6):888–897.
72. Takken T, Groen WG, Hulzebos EH, et al. Exercise stress testing in children with metabolic or neuromuscular disorders. *Int J Pediatr*. 2010;2010:254829. Epub 2010 Jul 15
73. Lanfranconi F, Ferri A, Corna G, et al. Inefficient skeletal muscle oxidative function flanks impaired motor neuron recruitment in Amyotrophic Lateral Sclerosis during exercise. *Sci Rep*. 2017;7(1):2951.
74. Stanghelle JK, Festvåg LV. Postpolio syndrome: a 5 year follow-up. *Spinal Cord*. 1997;35(8):503–508.
75. Knobil K, Becker FS, Harper P, et al. Dyspnea in a patient years after severe poliomyelitis. The role of cardiopulmonary exercise testing. *Chest*. 1994;105(3):777–781.
76. Jones DR, Speier J, Canine K, et al. Cardiorespiratory responses to aerobic training by patients with postpoliomyelitis sequelae. *JAMA*. 1989;261(22):3255–3258. PMID: 2654435.
77. Bankolé LC, Millet GY, Temesi J, et al. Safety and efficacy of a 6-month home-based exercise program in patients with facioscapulohumeral muscular dystrophy: a randomized controlled trial. *Medicine (Baltimore)*. 2016;95(31):e4497.
78. Scalco RS, Stemmerik M, Løkken N, et al. Results of an open label feasibility study of sodium valproate in people with McArdle disease. *Neuromuscul Disord*. 2020;30(9):734–741.
79. El Mhandi L, Millet GY, Calmels P, et al. Benefits of interval-training on fatigue and functional capacities in Charcot-Marie-Tooth disease. *Muscle Nerve*. 2008;37(5):601–610.
80. Ferri A, Lanfranconi F, Corna G, et al. Tailored Exercise Training Counteracts Muscle Disuse and Attenuates Reductions in Physical Function in Individuals With Amyotrophic Lateral Sclerosis. *Front Physiol*. 2019;10:1537.
81. Montes J, Garber CE, Kramer SS, et al. Single-Blind, Randomized, Controlled Clinical Trial of Exercise in Ambulatory Spinal Muscular Atrophy: why are the Results Negative? *J Neuromuscul Dis*. 2015;2(4):463–470.
82. Oncu J, Durmaz B, Karapolat H. Short-term effects of aerobic exercise on functional capacity, fatigue, and quality of life in patients with post-polio syndrome. *Clin Rehabil*. 2009;23(2):155–163.
83. Similä ME, Auranen M, Piirilä PL. Beneficial effects of ketogenic diet on Phosphofructokinase Deficiency (Glycogen Storage Disease Type VII). *Front Neurol*. 2020;11:57.
84. Wright NC, Kilmer DD, McCrory MA, et al. Aerobic walking in slowly progressive neuromuscular disease: effect of a 12-week program. *Arch Phys Med Rehabil*. 1996;77(1):64–69.
85. Gimenes AC, Bravo DM, Nápolis LM, et al. Effect of L-carnitine on exercise performance in patients with mitochondrial myopathy. *Braz J Med Biol Res*. 2015;48(4):354–362.
86. Lucia A, Maté-Muñoz JL, Pérez M, et al. Double trouble (McArdle's disease and myasthenia gravis): how can exercise help? *Muscle Nerve*. 2007;35(1):125–128.
87. Alemo Munters L, Dastmalchi M, Katz A, et al. Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis. *Arthritis Res Ther*. 2013;15(4):R83.
88. Taivassalo T, Gardner JL, Taylor RW, et al. Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions. *Brain*. 2006;129(Pt 12):3391–3401.
89. Braga ACM, Pinto A, Pinto S, et al. The Role of Moderate Aerobic Exercise as Determined by Cardiopulmonary Exercise Testing in ALS. *Neurol Res Int*. 2018;2018:8218697.
90. Cejudo P, Bautista J, Montemayor T, et al. Exercise training in mitochondrial myopathy: a randomized controlled trial. *Muscle Nerve*. 2005;32(3):342–350.
91. Florence JM, Hagberg JM. Effect of training on the exercise responses of neuromuscular disease patients. *Med Sci Sports Exerc*. 1984;16(5):460–465.

92. Rahbek MA, Mikkelsen EE, Overgaard K, et al. Exercise in myasthenia gravis: a feasibility study of aerobic and resistance training. *Muscle Nerve*. 2017;56(4):700–709.
93. Bean J, Walsh A, Frontera W. Brace modification improves aerobic performance in Charcot-Marie-Tooth disease: a single-subject design. *Am J Phys Med Rehabil*. 2001;80(8):578–582.
94. Bendahan D, Desnuelle C, Vanuxem D, et al. <sup>31</sup>P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies. *Neurology*. 1992;42(6):1203–1208.
95. Carroll JE, Brooke MH, DeVivo DC, et al. Biochemical and physiologic consequences of carnitine palmityltransferase deficiency. *Muscle Nerve*. 1978;1(2):103–110.
96. Marzorati M, Porcelli S, Bellistri G, et al. Exercise testing in late-onset glycogen storage disease type II patients undergoing enzyme replacement therapy. *Neuromuscul Disord*. 2012;22 Suppl 3(1):S230–4.
97. Nabben M, Schmitz JPJ, Ciapaite J, et al. Dietary nitrate does not reduce oxygen cost of exercise or improve muscle mitochondrial function in patients with mitochondrial myopathy. *Am J Physiol Regul Integr Comp Physiol*. 2017;312(5):R689–R701.
98. Roef MJ, de Meer K, Reijngoud DJ, et al. Triacylglycerol infusion improves exercise endurance in patients with mitochondrial myopathy due to complex I deficiency. *Am J Clin Nutr*. 2002;75(2):237–244.
99. Sunnerhagen KS, Darin N, Tajsharghi H, et al. The effects of endurance training in persons with a hereditary myosin myopathy. *Acta Neurol Scand*. 2004 Aug;110(2):80–86. Erratum in: *Acta Neurol Scand*. 2005;111(1):74. Tajsharghi, H [corrected to Tajsharghi, H]
100. van Den Berg LE, Favejee MM, Wens SC, et al. Safety and efficacy of exercise training in adults with Pompe disease: evaluation of endurance, muscle strength and core stability before and after a 12 week training program. *Orphanet J Rare Dis*. 2015;10:87.
101. Takken T, Custers J, Visser G, et al. Prolonged exercise testing in two children with a mild multiple Acyl-CoA-Dehydrogenase deficiency. *Nutr Metab (Lond)*. 2005 May 20;2(1):12. PMID: 15907213; PMCID: PMC1159171
102. Takken T, van der Net J, Engelbert RH, et al. Responsiveness of exercise parameters in children with inflammatory myositis. *Arthritis Rheum*. 2008;59(1):59–64.
103. Blom KJ, Takken T, Huijgen BCH, et al. Trajectories of cardiorespiratory fitness in patients with juvenile dermatomyositis. *Rheumatology (Oxford)*. 2017;56(12):2204–2211.
104. Pérez M, Maté-Muñoz JL, Foster C, et al. Exercise capacity in a child with McArdle disease. *J Child Neurol*. 2007;22(7):880–882.
105. Habers GE, Bos GJ, van Royen-kerkhof A, et al. Muscles in motion: a randomized controlled trial on the feasibility, safety and efficacy of an exercise training programme in children and adolescents with juvenile dermatomyositis. *Rheumatology (Oxford)*. 2016;55(7):1251–1262.
106. Lee PJ, Harrison EL, Jones MG, et al. L-carnitine and exercise tolerance in medium-chain acyl-coenzyme A dehydrogenase (MCAD) deficiency: a pilot study. *J Inherit Metab Dis*. 2005;28(2):141–152. PMID: 15877203
107. Omori C, Prado DM, Gualano B, et al. Responsiveness to exercise training in juvenile dermatomyositis: a twin case study. *BMC Musculoskelet Disord*. 2010;11:270.
108. Mousson B, Collombet JM, Dumoulin R, et al. An abnormal exercise test response revealing a respiratory chain complex III deficiency. *Acta Neurol Scand*. 1995;91(6):488–493.
109. Ortega F, Montemayor T, Sánchez A, et al. Role of cardiopulmonary exercise testing and the criteria used to determine disability in patients with severe chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 1994;150(3):747–751.
110. Boentert M, Wenninger S, Sansone VA. Respiratory involvement in neuromuscular disorders. *Curr Opin Neurol*. 2017 Oct;30(5):529–537.
111. Takken T, Mylius CF, Paap D, et al. Reference values for cardiopulmonary exercise testing in healthy subjects - an updated systematic review. *Expert Rev Cardiovasc Ther*. 2019;17(6):413–426.
112. Jones LW, Eves ND, Haykowsky M, et al. Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations. *Lancet Oncol*. 2008 Aug;9(8):757–765.
113. van Den Akker LE, Heine M, van der Veldt N, et al. Feasibility and safety of cardiopulmonary exercise testing in multiple sclerosis: A systematic review. *Arch Phys Med Rehabil*. 2015;96(11):2055–2066.
114. Myers J, Buchanan N, Walsh D, et al. Comparison of the ramp versus standard exercise protocols. *J Am Coll Cardiol*. 1991 May;17(6):1334–1342.
115. Lear SA, Brozic A, Myers JN, et al. Exercise stress testing. An overview of current guidelines. *Sports Med*. 1999;27(5):285–312.
116. Stickland MK, Butcher SJ, Marciniuk DD, et al. Assessing exercise limitation using cardiopulmonary exercise testing. *Pulm Med*. 2012;2012:824091. **Of interest: Provides evidence of CPET outcomes interpretation**
117. Haller RG, Lewis SF. Pathophysiology of exercise performance in muscle disease. *Med Sci Sports Exerc*. 1984 Oct;16(5):456–459. **Of interest: Provides evidence of CPET exercise limitation in NMDs**
118. Jones LW, Eves ND, Mackey JR, et al. Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer. *Lung Cancer*. 2007;55(2):225–232.
119. Abumehdi MR, Wardle AJ, Nazzari R, et al. Feasibility and safety of cardiopulmonary exercise testing in children with pulmonary hypertension. *Cardiol Young*. 2016;26(6):1144–1150.
120. Pane C, Salzano A, Trinchillo A, et al. Safety and feasibility of upper limb cardiopulmonary exercise test in Friedreich ataxia. *Eur J Prev Cardiol*. 2020 Dec 9;zwaa134. 10.1093/eurjpc/zwaa134
121. Knak KL, Andersen LK, Vissing J. Aerobic anti-gravity exercise in patients with Charcot-Marie-Tooth disease types 1A and X: a pilot study. *Brain Behav*. 2017;7(12):e00794.
122. Berthelsen MP, Husu E, Christensen SB, et al. Anti-gravity training improves walking capacity and postural balance in patients with muscular dystrophy. *Neuromuscul Disord*. 2014;24(6):492–498.